StrategyReport Sample

SAMPLE REPORT
Unique Data. Expert Analysis. Innovative Solutions. One Platform.
Pfizer Inc
Company Profile
Powered by GlobalData Company Analytics
Published: 17 Mar 2023

Report Code: CMT1408575
Table of Contents SAMPLE REPORT
COMPANY PROFILE DEAL STRATEGY Mentions and Growth by Region
Key Facts M&A Strategy Location Exposure
Company Financials Capital Raising Strategy Recent Filings
SWOT Analysis Strategic Alliances & Partnerships HIRING STRATEGY

Business Segments Corporate Venturing Hiring Trends
Corporate Strategy Advisor Strategy – Financial & Legal Advisors Hiring Theme Exposure
Key Executives RECENT DEVELOPMENTS Hiring by Location
News Trend and Sentiment Key Occupations and Skills

Industry Exposure
Product Development Days to Hire / Skill shortage
Locations & Subsidiaries
Management Changes Hiring Intensity by Seniority
BUSINESS STRATEGY
Business Expansion Senior Management Hiring
Top Selling Drugs
PATENT STRATEGY SOCIAL MEDIA & Ad STRATEGY
Drugs by Therapy Area
Patent Publication Trends Twitter Influencer Activity Trend
Drugs by Development Stage
Patents by Authority Reddit Activity Trend
Drugs by Therapy Area and Development Stage
Patents & IP Protection by Country/Region COMPETITIVE BENCHMARKING
Outsourcing Relationships
Top Innovators Key Facts
THEME STRATEGY Key Innovation Areas Financials
Theme Exposure Financial Ratios
Leader by Innovation & Disruptive Potential
Valuation Scorecard Deals Competitive Benchmarking
Key CPC Classifications
Risk Scorecard Patents Competitive Benchmarking
Recent Applications & Grants
DIGITAL LANDSCAPE & STRATEGY Hiring Activity Competitive Benchmarking
MANAGEMENT OUTLOOK
Technology Budget Estimates / ICT Budgets Social Media & Ads Competitive Benchmarking
Management vs. Analyst sentiment
ICT Contracts / Software & Services Contracts Filings Sentiment and Mentions
APPENDIX & ADDITIONAL RESOURCES
Install Base CXO Intent ( R&D Investment, Human Capital) 2
Source: GlobalData Company Analytics
Recent Partnerships Filing Theme Exposure
SAMPLE REPORT
Pfizer Inc
Company Profile
3
Pfizer Inc - Key Facts SAMPLE REPORT
Headquarters Sector Founded Market Cap Revenue Employees
United States of Pharmaceuticals and 1849 $2,23,976m $1,00,330m 79,000
America Healthcare
Company Summary
Pfizer Inc (Pfizer) discovers, develops, manufactures and commercializes biopharmaceuticals. The company offers products to treat various conditions such as cardiovascular,
metabolic and pain, cancer, inflammation, immune disorders and rare diseases. It also provides sterile injectable pharmaceuticals, biosimilars, active pharmaceutical
ingredients (APIs) and contract manufacturing services. Pfizer sells its products through wholesalers, retailers, hospitals, clinics, government agencies and pharmacies. It has
major manufacturing facilities in India, China, Japan, Ireland, Italy, Belgium, Germany, Singapore, and the US. The company provides its products in North America, South
America, Asia-Pacific, Australia, Europe, Africa and the Middle East. Pfizer is headquartered in New York, the US.
Key Themes Key Lists Peers Key Investments Key Acquisitions

- US: Big Biopharma Companies (Large Pfizer Inc PrescriberPoint Corp Global Blood Therapeutics Inc
Pharma & Large Biotech) by Revenue AbbVie Inc Ribon Therapeutics Inc Biohaven Pharmaceutical Holding
Artificial Intelligence: Leading Johnson & Johnson Carrick Therapeutics Ltd Company Ltd
Adopters in the Pharma sector Merck & Co Inc Anokion SA ReViral Ltd
Big Data: Leading Adopters in the F. Hoffmann-La Roche Ltd AgomAb Therapeutics NV Arena Pharmaceuticals Inc
Pharma sector Trillium Therapeutics Inc
Biosimilars: Leading Adopters in the
Pharma sector
Blockchain: Leading Adopters in the
Pharma sector
4
Company Financials SAMPLE REPORT
Company revenue and net income (US$M) for the past five years.
Revenue Net Income EPS ($)

Pfizer Inc Financials (US$M) Year
(US$M) (US$M)
100,330
2018 40,825 11,152 1.1

81,288
2019 41,172 16,273 1.2
2020 41,651 9,159 1.5

40,825 41,172 41,651
31,372
2021 81,288 21,980 4.1
21,980
16,273
11,152 9,159
2022 1,00,330 31,372 5.4
2018 2019 2020 2021 2022

Total Revenue Net Income
5
Sales by Region SAMPLE REPORT
Sales ($USM) by region for the past five years.
42,473
29,746
21,455 21,982
20,119 20,326 20,701 20,097
18,336
15,778
12,506
8,618 8,828 8,372

7,997 7,729 7,788
4,090 4,022 4,036
2018 2019 2020 2021 2022

Developed Europe Developed Rest of World Emerging Markets United States
Note: see appendix for region details 6

Research & Development SAMPLE REPORT
Pfizer’s R&D focuses on the development of novel medicines for the treatment of cancer, inflammation, immune disorders, cardiovascular diseases,
metabolic diseases and rare diseases, besides sterile injectables, anti-infectives and vaccines. In FY2021, the company spent US$13,829 million on R&D,
which as a percentage of revenue stood at 17.01%. As of February 8, 2022, Pfizer had 89 projects in clinical R&D. It has R&D facilities in California,
Massachusetts, Missouri, Connecticut and New York in the US; and Cambridge and Sandwich in the UK. The company owns numerous US and foreign
patents covering pharmaceutical and other products and their uses, product manufacturing processes, pharmaceutical formulations and intermediate
chemical compounds used in the manufacture of its products.
R&D spending as a % of Revenue R&D Expenses (US$M)
12,381
11,582
9,340
7,713 7,731
18.9% 18.8% 22.4%

14.3% 12.3%
2018 2019 2020 2021 2022 2018 2019 2020 2021 2022
7
SWOT Analysis - Strengths SAMPLE REPORT
Dominant Position Focus on Research and Development Core Segment: Biopharma
Pfizer is one of the world's premier innovative Pfizer carries out extensive research and development Biopharma was the major contributor to the company's
biopharmaceutical companies. Its global portfolio (R&D) to develop innovative medicines, targeting some of revenue in FY2022, accounting for 98.7% of its revenue. It
includes branded pharmaceuticals, biosimilars, and the major unmet medical needs. The company directs its consists of three categories such as Primary Care, Specialty
vaccines. The company’s blockbuster brands include R&D efforts to develop advanced medications for Care and Oncology. Primary Care includes internal medicine
Comirnaty, Paxlovid, Eliquis, Prevnar family, Ibrance, immunology and inflammation, cardiovascular and and vaccines product portfolios, products for COVID-19;
Vyndaqel family, Xeljanz, Xtandi, Mektovi, Lorbrena, metabolic diseases, cancer, vaccines, neurological diseases, Specialty Care provides the inflammation & immunology, rare
and Inlyta. With a global network of subsidiaries and and pain and rare diseases. It is developing a pipeline of disease and hospital products and oncology offers biologics,
employees, Pfizer sells its products in more than 125 next generation therapies including large-molecule small molecules, immunotherapies and biosimilars. Its major
countries. Besides its leadership position in the US, biologics, small-molecule therapies and vaccines based on products include Eliquis, Nurtec ODT/Vydura, the Premarin
Pfizer has a significant global presence with revenue in cutting-edge platforms to bring best-in-class therapies to family, The Prevnar family, Nimenrix, FSME/IMMUN-TicoVac,
international markets exceeding US$100 billion in patients. Its major R&D platforms include precision Trumenba, Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, Cibinqo,
FY2022. The company also provides services such as medicines, gene therapy, medicinal sciences and Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga,
transaction processing, accounting, IT, manufacturing, biosimilars. Pfizer has R&D facilities at La Jolla and San Ibrance, Xtandi, Inlyta, Retacrit, Lorbrena and Braftovi. Growth
clinical trial recruitment and execution, clinical lab Francisco, California; Andover and Cambridge, in the revenue of the major contributing segment augments
services, non-clinical research, safety services, Massachusetts; Pearl River, New York; Groton, Connecticut; the financial performance of the company. The Biopharma
integrated facilities management, and other areas. and St. Louis, Missouri in the US; and Sandwich and segment recorded revenue of US$98,988.0 million for FY2022,
Cambridge in the UK. In FY2022, the company spent which grew 24.4% YoY compared to US$81,288 million in
US$11,428 million on R&D, which as a percentage of FY2021. Revenue grew owing to increase in the sales of
revenue, stood at 11.4%... Paxlovid, Comirnaty, the Prevnar family, Eliquis, the Vyndaqel
family, Inlyta and Xtandi, and All other Vaccines. It also
reported increased revenues from Nurtec ODT/Vydura and
Oxbryta.
8
SWOT Analysis - Weakness SAMPLE REPORT
Product Recalls Reliance on Pharmaceutical Wholesalers
The company recalled some of its products as they had The company sells its products essentially to wholesalers.
safety issues or defects that could affect the The three largest wholesalers that buy the company’s
consumer’s confidence. Product recalls due to such products are McKesson Corp, AmerisourceBergen Corp, and
issues would hamper Pfizer brand image and affect the Cardinal Health Inc. In FY2022, these three wholesalers
sale of its products. In May 2022, the company has accounted for around 23% of Pfizer’s revenue and 32% of
recalled its Accuretic (quinapril accounts receivable. The loss or termination of one or more
HCl/hydrochlorothiazide) tablets and quinapril and wholesalers could hamper the sales of the company in the
hydrochlorothiazide and quinapril HCl/ market served by that wholesaler. If the company intends
hydrochlorothiazide) due to higher level presence of to distribute its products directly, it would have to invest in
nitrosamine, N-nitroso-quinapril in the products than sales, marketing, and administrative resources, including
the daily intake. These products are used in the field account executives and customer support resources,
treatment of hypertension. The company initiated a which would increase its expenses significantly.
recall of 6 lots to return its product.
9
SWOT Analysis - Opportunities SAMPLE REPORT
Strategic Acquisitions Strategic Agreements Approval of New Products
The company continues to view acquisitions as a major The company entered into strategic agreements to improve The company's ability to receive approval for its products will
part of its growth strategy. These acquisitions are its market presence and operational performance. As a part enable it to enhance operations and strengthen its market
intended to augment its growth, expand its business of business strategy, the company established alliances presence. In March 2023, the company’s ZAVZPRE
with new technologies and products, and enhance its with other companies that would help expand its business (zavegepant) Migraine Nasal Spray has received US Food and
geographical reach. In March 2023, the company and enhance its market share. In March 2023, the company Drug Administration (FDA) for the treatment of acute
agreed to acquire Seagen Inc for US$43 billion. The entered a new collaboration agreement with Cue Health to treatment of migraine. ZAVZPRET offers an alternative
acquisition helps in the expansion of the company’s raise awareness among individuals with certain underlying treatment option for people with migraine gain relief and get
oncology product portfolio. It’s major products include conditions about the risks of progressing to severe COVID- back to their daily lives. This increases the company’s migraine
Padcev for the treatment of bladder cancer; and other 19. The agreement helps in the faster and more convenient franchise by supporting billions of people worldwide. In
ADCs. Seagen’s ADC technology improves the services to customers. It improves the test-to-treatment February 2023, the company’s CIBINQO (abrocitinib) has
innovative cancer care and enhances the existing experience for patients and communities at high risk in received approval from US Food and Drug Administration
portfolio across both solid tumors and hematologic elder aged people with Covid-19. In February 2023, the (FDA). CIBINQO was approved to use in the treatment of
malignancies. In October 2022, the company has company announced a collaboration with Tempus under refractory, moderate-to-severe atopic dermatitis (AD). The
completed the acquisition of Global Blood Therapeutics which Pfizer will access to Tempus’ AI-enabled platform and product offers potential relief for young atopic dermatitis
for US$5.4 billion. The acquisition enhances the its library of de-identified, multimodal data to uncover patients in need and their families. This provides new
innovation of the company and improves the potential insights that will power therapeutic development in opportunities for the company in adolescents products. In
treatments to people living with sickle cell disease. This oncology. During this agreement, the company can also January 2023, the company secured an approval from
acquisition provides opportunity to transform the lives improve its therapeutic R&D to advance its own oncology herapeutic Goods Administration for bivalent COVID-19
of the patients suffering from sickle cell disease with portfolio of products along with its Tempus’ clinical trial vaccine. In December 2022, Pfizer Canada ULC and BioNTech
the help of Global Blood Therapeutics product portfolio matching program, TIME programmes... SE announced that Health Canada authorized COMIRNATY
and clinical trials. In the same month, the company Original & Omicron BA.4/BA.5 as a 10-µg booster dose for
completed the acquisition of the US-based Biohaven children 5 through <12 years of age...
Pharmaceutical Holding Company...
10
SWOT Analysis - Threats SAMPLE REPORT
Uncertain R&D Outcomes Competitive Environment Regulatory Oversight
Adverse or inconclusive results from preclinical testing Pfizer's markets are characterized by intense competition, Pfizer operates in a highly regulated industry, where a variety
or clinical trials may substantially delay or halt the evolving industry standards and business models. Its of statutes and regulations are in place for the testing,
development of the company's various product products face competition from the new and innovative manufacture, and sale of pharmaceutical products. The
candidates, consequently affecting its timeliness for products of its competitors. Competitors’ products may company has to obtain regulatory approvals before
profitability. The outcome of clinical trials is always a make the company’s products obsolete and non- commercializing its products. The company’s products,
subject of uncertainty. After the discovery of a new competitive, even before the company is able to recover research and development activities and manufacturing
compound, substantial amount of money and a great the costs associated with any such product’s research, processes are subject to various local, state, federal, foreign,
deal of time are required to successfully launch a new development, or commercialization. The company’s and transnational laws and regulations. In the US, the FDA; in
product. Moreover, it may become necessary to competitors include major US and Europe-based Europe, the European Medicines Agency (EMA); and in China,
discontinue clinical development if the effectiveness of pharmaceutical companies including Johnson & Johnson, National Medical Products Administration regulate the
the drug is not proven as initially expected, or if serious Merck and Co Inc, Novartis AG, F. Hoffmann-La Roche Ltd, manufacture, safety and quality of pharmaceutical products,
adverse effects arise. It is difficult to accurately foresee AbbVie Inc, Amgen Inc, AstraZeneca plc, Bristol-Myers the commercialization of new pharmaceutical products, and
when approvals for a new product can be obtained. Squibb Company, Eli Lilly & Co, and Sanofi. Several Pfizer’s labeling and record-keeping procedures. Receiving marketing
The company has a total of 110 projects in its product products face competition from generics, which could approval for new drugs is time-consuming and expensive.
pipeline portfolio. ultimately lead to price pressure, and loss of market Failure to comply with the present or future regulations
exclusivity for its blockbuster drugs. The highly competitive related to clinical, laboratory, and manufacturing practices
environment in the biotechnology and pharmaceutical may result in delayed approval of drugs, product recalls, and
domain is subject to rapid and substantial technological cancellation of permission to produce or sell drugs. With
changes. Its competitors could develop products which several products under development, the company faces a
offer an entirely different, safe, and effective approach or potential challenge from its competitors, which have obtained
means of accomplishing the desired therapeutic effect, and regulatory approval for marketing...
such products could also be less costly than its product
candidates...
11
Business Segments SAMPLE REPORT
Business Segment Overview Performance
• Includes innovative oncology brands of biologics, small molecules, • Reported revenue of US$12,132.0 million for FY2022, which
immunotherapies, and biosimilars for a wide range of cancers. decreased 1.6% YoY, and recorded a CAGR of 5.7% during 2020-22.
Oncology
• Major brands include Inlyta, Ibrance, Xtandi, Lorbrena, Braftovi, and Oncology accounted for 12.3% of the Biopharma's revenue in FY2022.
Retacrit... • Ibrance reported revenue of US$5,120.0 million in FY2022, ..
• Offers innovative brands for cardiovascular and metabolic diseases, • Reported revenue of US$73,023.0 million for FY2022, which grew
migraine and women’s health. It also offers regional brands. It provides 40.4% YoY, and recorded a CAGR of 116.5% during 2020-22. Primary
Primary Care
Vaccines product portfolio and products related to COVID-19 prevention Care accounted for 73.8% of the Biopharma's revenue in FY2022.
and treatment with antiviral products... • Comirnaty direct sales and alliance revenues reported re..
• Reported revenue of US$13,833.0 million for FY2022, which

• Includes hospital portfolio of sterile injectable and anti-infective
decreased 9% YoY, and recorded negative growth of 1.6% during
medicines. Also comprises active pharmaceutical ingredients and contract
Specialty Care 2020-22. Specialty Care accounted for 14.0% of the Biopharma's
manufacturing services. Also offers inflammation & immunology product
revenue in FY2022.
portfolio includes innovative brands a..
• Vyndaqel family reported revenue of US$2,447...
12
Corporate Strategy SAMPLE REPORT
➢ Pfizer is a US-based global biopharmaceutical company that applies science and its global resources to improve health
and well-being at every stage of life.
➢ Its corporate strategy is to aim at enhancing its in-line and patent protected pipeline portfolio in major areas with
significant opportunities for innovation and market leadership for its medicines meant for the treatment of cancer, pain,
inflammation, besides advancing vaccines and biologics. It also focuses on emerging markets to tap the immense
potential in the pharmaceutical and biopharmaceutical domains to augment its growth.
➢ It also aims at maintaining its existing partnerships and entering into new collaborative agreements to improve its
services. The company strives to achieve growth in emerging markets to capture new opportunities for its established
product portfolio. It invests in complementary businesses to develop a lower, more flexible cost base for the combined
entity. The company intends to take advantage of the scientific advances in new and more complex areas that will
enable it to address the challenges and meet the unmet medical needs and improve performance through its unique
and flexible business model.
13
Key Executives SAMPLE REPORT
Name Position Board Since Age
Aamir Malik Executive Vice President Senior Management 2021 47
Albert Bourla, Ph.D. Chairman, Chief Executive Officer Executive Board 2020 61
Angela Hwang Chief Commercial Officer, President - Global Biopharmaceuticals Business Senior Management 2019 57
Dan R. Littman, M.D., Ph.D. Director Non Executive Board 2018 70
David M. Denton Executive Vice President, Chief Financial Officer Senior Management 2022 57
Douglas M. Lankler General Counsel, Executive Vice President Senior Management 2013 57
Helen H. Hobbs, M.D. Director Non Executive Board 2011 70
James C. Smith Director Non Executive Board 2014 63
James Quincey Director Non Executive Board 2020 58
Joseph J. Echevarria Director Non Executive Board 2015 65
14
Industry Exposure SAMPLE REPORT
Top industries by exposure across all KPIs.
Industry News Deals Filings All KPIs
Healthcare
Technology, Media and Telecom
Government and Non-Profit Organisations
Consumer
Aerospace and Defence
Retail & Wholesale
Construction
Packaging
Financial Services
Transportation, Infrastructure and Logistics
Power & Utilities
Automotive
Industrial Goods & Machinery
Business and Consumer Services
Oil & Gas
15
Note: Industry exposure map showcases the industry focus of the company based on the level of exposure by signals. Source: GlobalData Company Analytics
Location Exposure SAMPLE REPORT
Top countries by exposure across all KPIs.
Location News Deals Filings Jobs Patents Social Media All KPIs
United States of America
China
Canada
United Kingdom
Australia
Japan
Germany
Israel
India
Brazil
Spain
South Korea
Russia
France
Belgium
16
Note: Location exposure map showcases the location focus of the company based on the level of exposure by signals. Source: GlobalData Company Analytics
Locations & Subsidiaries SAMPLE REPORT
Headquarters Key locations & Subsidiaries
235 E 42nd St, New York, New York, Pfizer Srl1st Floor, Sector B - South Pfizer (Malaysia) Sdn Bhd Wisma
United States of America, 10017- Side,Complejo Thames Office Averis, Tower 2,Avenue 5, Bangsar
5703 Park,Colectora Panamericana 1804, South, Jalan Kerinchi, Wilayah
1 212 5732323 Buenos Aires, Ciudad Autonoma De Persekutuan, Kuala Lumpur (Federal
1 302 6555049 Buenos Aires, Argentina, Zip Code: Territory of), Malaysia, Zip Code:
www.pfizer.com B1607EEV 59200
17
Locations & Subsidiaries SAMPLE REPORT
Key locations & Subsidiaries
King Pharmaceuticals Canada, Inc. 2915 Argentia Road, Suite 7, Pfizer Inc 19-20 Floors, 8 Rockwell Building Hidalgo Drive Rockwell Center,
Mississauga, Ontario, L5N 8G6, Canada, 2915 Argentia Road, Suite 7, Poblacion, Makati, Manila, Philippines, Zip Code: 1210
Mississauga, Ontario, Canada
Pfizer (Thailand) Ltd Floor 36 and 37, United Center Building, 323 Silom Wyeth Industria Farmaceutica Ltda No. 1860, 3rd Floor, Rua Alexandre
Road, Silom, Bangrak, Bangkok (Krung Thep Maha Nakhon), Thailand, Dumas, Chacara Santo Anton, Sao Paulo City, Sao Paulo, Brazil, Zip Code:
Zip Code: 10500 04717-904
Pfizer Pharmaceuticals Ltd 8-12/F, The Fifth Square, Tower B, No. 3-7 Haptogen Ltd C/O Cms Cameron Mckenna Llp, Saltire Court, 20 Castle
Chaoyangmen North Avenue, Dongcheng District, Beijing, Beijing, China, Terrace, Edinburgh, Scotland, United Kingdom, Zip Code: EH1 2EN
Zip Code: 100010
Pfizer Venezuela SA Edif. Pfizer Av. Principal de los Ruices,entre 2da y Wyeth Pakistan Ltd Room No. 002 and 003, PGS Admin Block, 1st Floor, Plot
3era transversal, Caracas, Distrito Capital, Venezuela, Zip Code: 1071 No. B-2, S.I.T.E., Karachi, Sindh, Pakistan, Zip Code: 75730
D.C.
Wyeth Limited (Inactive) Plot No. C-59, Level 6, Platina, G Block Bandra - Therachon SAS Parc Valrose, Bat Sci Nat 8th floor, Nice cedex 2, Nice,
Kurla Complex, Bandra (E), Mumbai, Maharashtra, India, Zip Code: Provence - Alpes- Cote d'Azur, France, Zip Code: 06108
400098
18
Contact us for full list of locations & subsidiaries Source: GlobalData Company Analytics
SAMPLE REPORT
Pfizer Inc
Business Strategy
19
Top Selling Drugs SAMPLE REPORT
Top selling drugs in 2022.
20
Drugs by Therapy Area SAMPLE REPORT
Drug count by therapy area
Central Nervous System 590
Infectious Disease 472
Oncology 407
Cardiovascular 351
Respiratory 332
Gastrointestinal 289
Dermatology 227
Immunology 200
Metabolic Disorders 198
Musculoskeletal Disorders 193
Genito Urinary System And Sex Hormones 167
Ear Nose Throat Disorders 160
Central Nervous System Drugs by Type
Ophthalmology 119
Women's Health 117
Hematological Disorders 94
Hormonal Disorders 63 Generic
Toxicology 45 37%
Male Health 31
Innovator
Undisclosed 30 63%
Genetic Disorders 30
Other Diseases 22
Mouth and Dental Disorders 19
Nutritional Disorders 10
Non Malignant Disorders 10 21
Drugs by Development Stage SAMPLE REPORT
Drug count by development stage.
1,044
897
612
356
134 138 125

70 90
24 40 19
6 1 7
22
Drugs by Therapy Area and Development Stage SAMPLE REPORT
Filing
Withdrawn Archived Pre- IND/CTA
Therapy Area Marketed rejected/Withd Phase III Phase II Phase I Phase 0 Preclinical Discovery Unknown Inactive Discontinued
(Marketed) (Marketed) Registration Filed
rawn
Cardiovascular 211 187 9 - - 5 4 2 - 1 5 1 1 40 31
Central Nervous System 271 222 18 2 2 11 21 14 - 1 24 6 1 148 89
Dermatology 136 109 8 2 - 5 6 11 - - 3 - 1 22 15
Ear Nose Throat Disorders 108 87 8 - - 1 1 1 - 1 - 1 - 2 1
Gastrointestinal 167 124 7 3 1 6 12 10 - - 5 2 1 37 25
Genetic Disorders 4 4 - 1 - 4 7 1 - - 1 1 1 12 5
Genito Urinary System And
110 106 7 - 1 2 1 4 - - 4 1 - 9 2
Sex Hormones
Hematological Disorders 54 40 1 1 - 7 2 1 - - 9 - - 9 3
Hormonal Disorders 37 42 - - 1 1 1 - - - - - - 2 1
Immunology 60 54 1 1 - 4 10 7 - - 10 3 - 78 34
Infectious Disease 212 217 17 7 - 19 24 24 - 1 26 9 6 93 28
Male Health 20 14 1 - - - 1 - - - - - - 6 1
Metabolic Disorders 75 56 3 - - 1 6 4 - - 7 1 1 58 44
Mouth and Dental
14 8 - - - 1 - - - - - - - 1 -
Disorders
Musculoskeletal Disorders 114 96 4 - - 3 5 3 - - 3 1 - 20 20
Non Malignant Disorders 5 - - 3 - 2 5 1 - - 1 - - 2 -
Nutritional Disorders 5 4 1 - - - - - - - - - - 1 -
Oncology 118 87 10 5 1 34 64 65 1 3 39 10 4 172 86
Ophthalmology 57 75 - - - 1 1 1 - - - - 1 10 3
Other Diseases 15 10 1 - - - 1 - - - - - - 1 -
Respiratory 194 173 11 - - 3 3 1 - - 3 2 1 37 17
Toxicology 34 23 - - - 1 - - - - - - 1 6 2
Women's Health 81 56 6 - - 1 - - - - 3 - - 12 5
Undisclosed - - - - - - - 3 - - 4 4 1 17 1
23
Outsourcing Relationships (CROs and CMOs) SAMPLE REPORT
Trials with CROs by Phase Outsourced drugs by Molecule Type

Phase III/IV
Phase II/III 1%
Phase I/II 3%
4%
Biologic
13%
Phase IV
8%
Phase I
34%
Phase II
23%
Small Molecule
87%
Phase III
27%
Phase I Phase III Phase II Phase IV Phase I/II Phase II/III Phase III/IV Small Molecule Biologic
24
Top CMOs SAMPLE REPORT
No. of Drugs
4
Aenova Holding GmbH 5
0
5
Recipharm AB 6
1
0
Cambrex Corp 0
6
4
Vetter Pharma-Fertigung GmbH & Co KG 6
0
1
Corden Pharma International GmbH 0
5
8
PCI Pharma Services 1
0
7
Fareva SA 6
1
9
Siegfried Holding AG 9
3
8
Patheon NV 15
0
10
Catalent Inc 17
2
0 2 4 6 8 10 12 14 16 18
Packager Dose Manufacturer API Manufacturer

25
Top CROs SAMPLE REPORT
PPD Inc 52
PMG Research Inc 51
Sarah Cannon Research Institute LLC 46
IQVIA Holdings Inc 33
ICON Plc 30
Syneos Health Inc 28
PRA Health Sciences Inc 27
Anaheim Clinical Trials-LLC 26
Parexel International Corp 26
Miami Research Associates LLC 25
No. of Clinical Trials
26
SAMPLE REPORT
Pfizer Inc
Theme Strategy
27
Theme Exposure (by Signal) SAMPLE REPORT
Top themes by exposure across all KPIs.
Theme News Deals Filings Jobs Patents Social Media All KPIs
Regulation
Healthtech
COVID-19
Strategic Partnerships
ESG - Environmental
Digitalization
Big Data
Smart Hospitals
M&A
ESG - Governance
Artificial Intelligence
ESG - Social
Funding
Precision Medicine
Genomics
28
Note: Theme exposure map showcases the theme focus of the company based on the level of exposure by signals and by time Source: GlobalData Company Analytics
Theme Exposure (by Time) SAMPLE REPORT
Top themes by exposure across all KPIs.
Theme 2018 2019 2020 2021 2022
COVID-19
Regulation
Healthtech
ESG - Environmental
Strategic Partnerships
M&A
Genomics
Smart Hospitals
ESG - Governance
Digitalization
Remote Patient Monitoring
Machine Learning
Real World Evidence
Funding
29
Note: Theme exposure map showcases the theme focus of the company based on the level of exposure by signals and by time Source: GlobalData Company Analytics
Valuation Scorecard SAMPLE REPORT
The valuation screen tells us whether the publicly listed players appear cheap or expensive relative to their peers, based on consensus
forecasts from investment analysis.
Pharma Valuation Screen

30 companies Weighting 25% 20% 15% 20% 20% 100%
Company MKT CAP Ticker Country EV/EBITDA P/E EBIT margin % EV/FCF Div yield % Valuation
(US$ M) Ranking
Pfizer 223,976 PFE USA 5.7 7.1 36.4 9.1 4 1
GSK 68,665 GSK UK 8 3.8 21.9 13.4 6.2 2
Sanofi 119,083 SAN France 8.5 13.3 23.5 14.3 3.8 3
Viatris 11,765 VTRS USA 6.4 5.7 9.9 11.8 4.9 4
AbbVie 268,860 ABBV USA 12.1 22.7 31.2 13.3 3.7 5
Roche 233,962 ROG Switzerland 11.1 17.4 27.6 17.4 3.6 6
Amgen 124,513 AMGN USA 11.9 19 36.3 17.5 3.4 7
Gilead Sciences 99,157 GILD USA 12.5 21.6 26.9 14.1 3.7 8
Bristol Myers Squibb 138,519 BMY USA 8.5 21.9 20.9 14.1 3.3 9
Bayer 59,090 BAYN Germany 6.4 13.3 13.8 20.8 3.6 10
Takeda 50,313 4502 Japan 10 29.5 12.5 11 4.2 11
Zhifei Biological 20,375 300122 China 11.4 13.8 39.1 20.9 0.6 12
CSPC 11,893 1093 China 9.4 14.6 24.5 25.1 2.1 13
Merck & Co 268,405 MRK USA 13.1 18.5 30.3 19.4 2.6 14
Novartis 192,938 NOVN Switzerland 12.3 27.7 17.8 17.5 3.9 15
BASF 43,827 BAS Germany 5.6 -65.2 7.5 18 7.5 16
Johnson & Johnson 398,612 JNJ USA 14.5 22.2 22.9 24.1 2.9 17
Zydus Lifesciences 5,758 ZYDUSLIFE India 14.2 10.5 18 56.4 0.8 18
Novo Nordisk 245,147 NOVO B Denmark 20.9 30.9 42.3 26.8 1.5 19
Vertex 75,446 VRTX USA 14.6 22.7 48.2 16.6 0 20
Regeneron 82,249 REGN USA 15.2 19 38.9 22.7 0 21
Biogen 37,357 BIIB USA 12.6 12.3 25.2 33.9 0 22
Cipla 8,615 CIPLA India 15.3 28.1 15.3 25.6 0.6 23
Celltrion 17,224 068270 Korea 24.5 39.5 36.3 38 0 24
Charles River 10,300 CRL USA 13.2 21.2 16.9 43.5 0 25
CSL 89,833 CSL Australia 24.8 39.8 27.7 64.5 1.2 26
Lilly 309,027 LLY USA 37.4 49.5 25 70.3 1.1 27
AstraZeneca 199,203 AZN UK 24 60.6 8.5 30.7 2.2 28
Dr. Reddy's 8,857 DRREDDY India 19 33.3 12.1 79 0.6 29
Reliance Industries 183,421 RELIANCE India 15.3 24.8 11.7 152.1 0.3 30
30
Risk Scorecard SAMPLE REPORT
The risk screen tells us who the riskiest players in each industry are, based on our assessment of four risk categories: operational risk, financial risk, industry risk, country risk.
Pharma Risk Screen
30 companies Weighting 40% 30% 15% 15% 100%
Company MKT CAP Ticker Country Operational Risk Financial Risk Industry Risk Country Risk Risk
(US$ M) Ranking
Vertex 75,446 VRTX USA 4 4 4 5 1
Regeneron 82,249 REGN USA 4 4 4 5 2
Roche 233,962 ROG Switzerland 4 3 4 5 3
Lilly 309,027 LLY USA 4 3 4 5 4
AbbVie 268,860 ABBV USA 4 3 4 5 5
Novartis 192,938 NOVN Switzerland 4 3 4 5 6
Jiangsu Hengrui Medicine 38,279 600276 China 3 4 4 4 7
Seagen 36,919 SGEN USA 3 4 4 5 8
CSPC 11,893 1093 China 3 4 3 4 9
Charles River 10,300 CRL USA 4 3 4 5 10
Biogen 37,357 BIIB USA 4 3 4 5 11
Johnson & Johnson 398,612 JNJ USA 4 3 4 4 12
Merck & Co 268,405 MRK USA 4 3 4 4 13
Zhifei Biological 20,375 300122 China 4 3 4 4 14
Bristol Myers Squibb 138,519 BMY USA 4 3 4 5 15
Lonza 42,521 LONN Switzerland 4 3 4 5 16
Novo Nordisk 245,147 NOVO B Denmark 4 4 4 4 17
Parexel 0 Unlisted USA 3 3 4 5 18
Patheon 0 Unlisted Netherlands 3 3 4 5 19
Daiichi Sankyo 62,761 4568 Japan 3 4 4 5 20
Gilead Sciences 99,157 GILD USA 4 3 4 5 21
PPD 0 Unlisted USA 3 3 4 5 22
Sanofi 119,083 SAN France 3 3 4 4 23
WuXi AppTec 33,325 603259 China 3 3 4 4 24
Amgen 124,513 AMGN USA 4 2 4 4 25
Dr. Reddy's 8,857 DRREDDY India 3 3 4 4 26
Celltrion 17,224 068270 Korea 3 3 4 5 27
CSL 89,833 CSL Australia 3 3 4 4 28
Cadila 0 Unlisted India 3 3 4 3 29
BASF 43,827 BAS Germany 3 2 3 5 30
31
SAMPLE REPORT
Pfizer Inc
Digital Landscape & Strategy
32
Digital Strategy: Estimated ICT Budget for 2022 SAMPLE REPORT
Breakdown of ICT budget by spending category, 2022(US$m)
Spending category US$M
Internal development and maintenance spend 1,215
External spend 2,356
US$m 3,572
Total ICT spend by function, 2022 Total IT spend by channel, 2022
10% Data Centre Technology

9%
19% 18%
Service Desk 8% Local Resellers of
18% End-User Computing Telco
5%
9% Network Internal
14%
Applications Systems
12% Communications Specialist
16%
Management 35% 11%
ICT Services
16%
33
Digital Strategy: Estimated ICT Budget for 2022 SAMPLE REPORT
External ICT spend by segment, 2022 Network and Communications 370
Managed IP telephony service (IP-PBX, IP-Centrex) 17
Fixed voice (excluding VoIP) 58
1%
Hardware VoIP 7
16% 18% Broadband 46
Software
Mobile Communication 89
Services Conferencing and Collaboration services 11
11%
Consulting Network services 121
30% SD-WAN 7
Communications
Other 9
24%
Other
Software (Inc Cloud SaaS) 689
Enterprise applications 204
Data management and analytics 92
Breakdown of external ICT budget by segment, 2022 $M Communication and Collaboration software 41
Security 59
Hardware (including cloud IaaS) 435 Storage 27
Network Equipment 65 ICT infrastructure management (excluding SD-WAN) 171
Security Equipment 22 Software defined Networking/SD-WAN 12
Servers 88 Other 82
Storage 64 ICT Services 567

Desktop PCs/Laptops/Printers 112 Application services 183
Communication Devices (Conferencing Phones, Interactive Screens, Mobile Phones) 76 Hosting & data center services 180
Other 8 Security & privacy services 35
Desktop services & user support 65
Consulting 268 Storage Services 18
Systems planning & design consulting 130 Cloud management services 34
Security consulting 51 Systems integration 18
Other 33
Training, education, and other consulting 57
Other 30 Other 29
34
Major ICT Contracts SAMPLE REPORT
Contract duration Total Contract IT solutions area /
Primary vendor Start date End date Signing region
(months) Value(US$M) primary IT service type
Anumana Inc 16-Dec-2022 15-Dec-2025 36 15.43 Services United States of America
Amazon Web Services Inc 02-Dec-2021 01-Dec-2024 36 3.50 Services United States of America
Dell Technologies Inc 29-Apr-2019 28-Apr-2024 60 25.12 Services United States of America
ADOBE Inc 04-Jan-2021 03-Jan-2024 36 5.64 Software United States of America
NVIDIA Corp 24-May-2020 23-May-2023 36 12.32 Software United States of America
Komprise Inc 26-Apr-2020 25-Apr-2023 36 1.85 Software United States of America
QPC Limited 23-Nov-2017 22-Nov-2020 36 4.35 Services Australia
Invoiceware International, LLC 29-Sep-2015 28-Sep-2018 36 5.50 Services United States of America
Unitedlex Corporation 05-Jun-2013 04-Jun-2018 60 12.00 Services United States of America
Dassault Systemes SE 07-May-2013 06-May-2016 36 2.40 Services United States of America
35
Install Base SAMPLE REPORT
Top Vendors by intensity*.
Vendor Name Product Name IT Solution IT Infrastructure IT Segment Last Reviewed Intensity
Business Process
Microsoft Corp Microsoft Office Software/Application Office Productivity Applications 19 May 2022 3,673
Applications
Business Process
Microsoft Corp Microsoft Excel Software/Application Office Productivity Applications 20 May 2022 1,490
Applications
Business Process
Microsoft Corp Microsoft Word Software/Application Office Productivity Applications 18 May 2022 1,095
Applications
Open Text Corp OpenText ProVision IT Management Software/Application Business Process Management 24 May 2022 934
Microsoft Corp Microsoft (Unstated Product) Other Other Others 21 May 2022 930
Application Lifecycle
Python Software Foundation python IT Management Software/Application 23 May 2022 824
Management
Business Process Supply Chain Management

SAP SE SAP Ariba Software/Application 25 Dec 2021 794
Applications Applications
Business Intelligence and Data

Tableau Software LLC Tableau (Unstated Product) Data and Analytics Software/Application 23 May 2022 748
Discovery Tools
Business Process Human Resource and Payroll

Workday Inc Workday (Unstated Product) Software/Application 20 May 2022 675
Applications Applications
Oracle Corp Oracle (Unstated Product) IT Management Software/Application Database Management 19 May 2022 593
*Note: Intensity refers to the number of individual/independent data from which we confirm the relationship between the client (prospect) and the 36
vendor (the technology provider). The higher the number the greater our confidence level that a client-vendor relationship exists between the two.
Install Base SAMPLE REPORT
Top Vendors by intensity.
37
Digital Landscape: Recent Partnerships SAMPLE REPORT
Date Headline Partner Geography
28 Feb 2023 Tempus Enters into Co-Development Agreement with Pfizer Tempus Labs Inc United States
Vysioneer announces data sharing agreement with Pfizer to augment oncology clinical
21 Feb 2023 Vysioneer Inc United States
trials with Artificial Intelligence
13 Dec 2022 Annogen announces research project with Pfizer to test Non-coding Genetic Sequences United States; Netherlands
Fox Chase Cancer Center and Sylvester Comprehensive Cancer Center collaborate with
10 Nov 2022 Fox Chase Cancer Center United States
Pfizer’s Institute of Translational Equitable Medicine
21 Oct 2022 Erasca and Pfizer enter trial partnership for palbociclib Erasca Inc United States
21 Sep 2022 Pfizer and CytoReason extend partnership for AI-driven drug discovery CytoReason Ltd Israel; United States
Truveta announces strategic collaboration with Pfizer to accelerate safety insights in real
21 Jun 2022 United States
time
17 Mar 2022 CENTOGENE announces expansion of data access and collaboration agreement with Pfizer Centogene NV Germany; United States
CytoReason and Pfizer extend collaboration to leverage machine learning in drug

10 Feb 2022 CytoReason Ltd Israel; United States
development
09 Feb 2022 Iterative Scopes, Pfizer enter AI-driven data sharing agreement to support IBD trials Iterative Scopes Inc United States
38
SAMPLE REPORT
Pfizer Inc
Deal Strategy
39
M&A Strategy SAMPLE REPORT
Value and volume of mergers and acquisitions made in last 5 years.
20,000 5
18,000
16,000 4
14,000
12,000 3
Deal Value US$M
Deal Volume
10,000
8,000 2
6,000
4,000 1
2,000
0 0
2018 2019 2020 2021 2022
Deal Value US$(m) 0 12,366 0 8,960 18,252
Deal Volume 1 4 1 4 4
40
M&A Strategy SAMPLE REPORT
Volume of divestments made in last 5 years.
6
5
5
4
4
Deal Volume
3
3
1
1
0
0
2018 2019 2020 2021 2022
41
M&A Strategy (Recent Acquisitions and Divestments) SAMPLE REPORT
Issuer/Partner/
Deal Value Acquirer/Investor/
Announced Date Headline Deal Type Deal Status Target/ Vendor
(US$M) Client
Service Provider
Pfizer to Acquire Seagen for USD43

13 Mar 2023 Acquisition Announced 43,000.0 Pfizer Inc Seagen Inc -
Billion
Pfizer to Acquire Manufacturing Site

17 Jan 2023 Asset Transaction Announced n/a Pfizer Inc - Abzena Ltd
from Abzena
Dr Reddy's Acquires Trademark Pfizer Products India

13 Jan 2023 Asset Transaction Completed n/a Dr. Reddy's Laboratories Ltd -
Rights from Pfizer Products Private Limited
Pfizer Acquires Global Blood Global Blood

08 Aug 2022 Acquisition Completed 5,400.0 Pfizer Inc -
Therapeutics Therapeutics Inc
Biohaven
Pfizer Acquires Remaining Stake in
10 May 2022 Acquisition Completed 12,210.5 Pfizer Inc Pharmaceutical -
Biohaven Pharma
Holding Company Ltd
Pfizer Australia Acquires ResApp

11 Apr 2022 Acquisition Completed 116.1 Pfizer Australia Holdings Pty Ltd ResApp Health Ltd -
Health
Pfizer Acquires ReViral from Andera

07 Apr 2022 Acquisition Completed 525.0 Pfizer Inc ReViral Ltd Andera Partners
Partners
Biohaven Pharma Acquires Channel Channel Biosciences Knopp Biosciences

24 Feb 2022 Acquisition Completed 1,237.5 Biohaven Ltd
Biosciences from Knopp Biosciences LLC LLC
42
Capital Raising Strategy SAMPLE REPORT
Capital raised in the last 5 years.
9,000 20
8,000 18
16
7,000
14
6,000
12
Deal Value US$M
5,000
Deal Volume
10
4,000
8
3,000
6
2,000
4
1,000 2
0 0
2018 2019 2020 2021 2022
Deal Value US$(m) 6,238 5,515 7,908 1,549 302
43
Note: Capital raised through Debt or Equity offerings are considered Source: GlobalData Company Analytics
Strategic Alliances & Partnerships SAMPLE REPORT
Partnership activity in last 5 years.
50
46
45
40 39
35
32
Deal Volume
30
26
25
20 18
15
10
0
2018 2019 2020 2021 2022
44
Recent Strategic Alliances & Partnerships SAMPLE REPORT
Announced Date Headline Deal Type Deal Status
28 Feb 2023 Tempus Enters into Co-Development Agreement with Pfizer Partnership Completed
06 Jan 2023 Gero Entered into Research Agreement with Pfizer Partnership Completed
21 Dec 2022 ORIC Pharma Enters into Agreement with Pfizer Partnership Completed
19 Dec 2022 Pfizer Enters into Licensing Agreement with LianBio Licensing Agreement Completed
15 Dec 2022 Pfizer Enters into Co-Development Agreement with Anumana Partnership Completed
06 Dec 2022 Pfizer Enters into Licensing Agreement with Clear Creek Bio Licensing Agreement Completed
King Abdulaziz City for Science and Technology (KACST) Enters into Agreement with Pfizer
01 Dec 2022 Partnership Completed
Saudi
01 Dec 2022 Roivant and Pfizer Form New Vant Company Partnership Completed
28 Oct 2022 Pfizer Investment Enters into Licensing Agreement with Ascletis Pharma Licensing Agreement Completed
20 Oct 2022 Erasca Enters into Agreement with Pfizer Partnership Completed
45
Corporate Venturing SAMPLE REPORT
Value and volume of investments in last 5 years.
1,600 18
1,400 16
14
1,200
12
1,000
Deal Value US$M
10
Deal Volume
800
8
600
6
400
4
200 2
0 0
2018 2019 2020 2021 2022
Deal Value US$(m) 1,015 447 596 1,517 933
46
Corporate Venturing (Recent Investments) SAMPLE REPORT
Issuer/Partner/
Announced
Headline Deal Type Deal Status Deal Value (US$M) Acquirer/Investor/Client Target/
Date
Service Provider
PrescriberPoint Raises Funds through Seed
31 Jan 2023 Venture Financing Completed n/a Eli Lilly and Co,Mastercard Inc,Pfizer Inc,... PrescriberPoint Corp
Financing
VitaDAO Raises USD4.1 Million in Venture Joe Betts-Lacroix,Balaji

30 Jan 2023 Venture Financing Completed 4.1 VitaDAO
Financing Srinivasan,Undisclosed,...
Grey Wolf Therapeutics Raises USD49 Million Earlybird Venture Capital GmbH & Grey Wolf Therapeutics
26 Jan 2023 Venture Financing Completed 49.0
in Series B Financing Co KG,Andera Partners,Canaan Inc,... Ltd
Seroba Life Sciences Management

Storm Therapeutics Raises USD30 Million in
14 Dec 2022 Venture Financing Completed 30.0 Ltd,Cambridge Innovation Capital Storm Therapeutics Ltd
Series B Financing
Plc,Pfizer Ventures LLC,...
Pfizer Venture Investments,RA Capital
Jnana Therapeutics Raises USD107 Million in
15 Nov 2022 Venture Financing Completed 107.0 Management LP,Versant Venture Jnana Therapeutics Inc
Series C Financing
Management LLC,...
British Patient Capital Ltd,M
Nucleome Therapeutics Raises USD42.47 Nucleome Therapeutics
19 Oct 2022 Venture Financing Completed 42.5 Ventures,Johnson & Johnson
Million in Series A Financing Ltd
Innovation - JJDC Inc,...
Capstan Therapeutics Raises USD102 Million in Polaris Partners LLC,RA Capital

14 Sep 2022 Venture Financing Completed 102.0 Capstan Therapeutics Inc
Series A Financing Management LP,Novartis Venture Fund,...
Autobahn Therapeutics Raises USD32.7 Million GT Healthcare Capital Partners LP,Bristol-

08 Sep 2022 Venture Financing Completed 32.7 Autobahn Therapeutics Inc
in Venture Financing Myers Squibb Co,Pfizer Ventures LLC,...
AgomAb Therapeutics Raises USD40.5 Million Walleye Capital,Pfizer Inc,Sabadell Asabys

13 Jul 2022 Venture Financing Completed 40.5 AgomAb Therapeutics NV
in Extended Series B Financing Health Innovation Investments SA,...
Longwood Fund Management LLC,UTokyo

DEM BioPharma Raises USD70 Million in
23 Jun 2022 Venture Financing Completed 70.0 Innovation Platform Co Ltd,Astellas DEM Biopharma Inc
Venture Financing
Venture Management LLC,...
47
Advisor Strategy – Financial Advisors SAMPLE REPORT
Top Advisors by deal volume in the last 5 years
Financial Advisors
Company Name Country # Deals Deal Value (US$M)
The Goldman Sachs Group Inc United States; China; ... 25 21,933.7
Deutsche Bank AG United States 17 16,500.0
Morgan Stanley United States;Australia 17 25,872.4
Barclays Plc United States 16 15,000.0
Bank of America Corp United States; Canada; ... 14 18,401.2
Citigroup Inc United States 14 10,785.0
J.P. Morgan Securities LLC United States 13 15,792.0
Centerview Partners LLC United States; Canada; ... 11 82,145.5
Credit Suisse Securities USA LLC United States 10 8,816.2
Royal Bank of Canada United States 9 8,737.5
48
Advisor Strategy –Legal Advisors SAMPLE REPORT
Top Advisors by deal volume in the last 5 years
Legal Advisors
Company Name Country # Deals Deal Value (US$M)
Skadden, Arps, Slate,... United States;Canada;France 22 41,248.1
Goodwin Procter LLP United States; Canada; ... 21 10,463.4
Cooley LLP United States; China; ... 15 10,978.2
Simpson Thacher & Bartlett LLP United States 17 16,500.0
Latham & Watkins LLP United States;Canada 8 6,005.8
Ropes & Gray LLP United States;Canada;China 9 22,594.2
Sullivan & Cromwell LLP United States 8 57,630.0
DLA Piper LLP Australia; United States; ... 5 1,405.6
Baker & McKenzie LLP Canada;Switzerland 5 2,519.9
Clifford Chance LLP China; United Kingdom; ... 5 1,005.0
49
SAMPLE REPORT
Pfizer Inc
Recent Developments
50
News Trend and Sentiment SAMPLE REPORT
180 1.05
160
1
140
120 0.95
Net Sentiment Score

News Count
100
0.9
80
60 0.85
40
0.8
20
0 0.75
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Q3 2019
Q4 2019
Q1 2020
Q2 2020
Q3 2020
Q4 2020
Q1 2021
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Q3 2022
Q4 2022
Quarter
News Count Net Sentiment Score

51
Product Development SAMPLE REPORT
Product development related news in the trailing 3 years.
Location Exposure Related Companies
Recent Developments
Announced Date Headline
13 Mar 2023 Astellas announces phase 3 China ARCHES study of XTANDI meets primary endpoint
10 Mar 2023 Pfizer’s ZAVZPRET (zavegepant) migraine nasal spray receives FDA approval
01 Mar 2023 Pfizer and BioNTech submit for U.S. emergency use authorization of omicron BA.4/BA.5-adapted bivalent COVID-19 booster in children under 5 years
28 Feb 2023 Pfizer receives positive FDA Advisory Committee votes supporting potential approval for vaccine candidate to help combat RSV in older adults
24 Feb 2023 Pfizer receives additional approval for Precedex as new sedative option for children in Japan
52
Management Changes
Management changes in the trailing 3 years.
SAMPLE REPORT
Date Headline Geography
03 Nov 2022 Pfizer names new head of digital health United States
06 Oct 2022 Pfizer appoints Deb Mangone as Ireland country manager United States
Biohaven sets new course with $258 million in cash, a proven team and deep pipeline to continue its journey to advance
04 Oct 2022 United States
science for patients
31 Aug 2022 Pfizer lures first chief marketing officer from Verily United States
31 Aug 2022 Pfizer Biopharmaceuticals Group hires Drew Panayiotou as global CMO China
The International Science Reserve announces executive board and unveils its first crisis activation on wildfire prevention
14 Apr 2022 United States
and management
11 Apr 2022 Pfizer names David M. Denton Chief Financial Officer United States
02 Feb 2022 Pfizer announced resignation of Mr. R. A. Shah as Chairman of the Board United States
01 Feb 2022 Pfizer Announces New Chief Development Officer United States
17 Jan 2022 ReViral Appoints Brett Haumann as Chief Medical Officer United Kingdom
08 Dec 2021 ResApp establishes COVID-19 Scientific Advisory Board Australia
06 Dec 2021 Biohaven Names CEO Vlad Coric, MD, Chairman Of The Board Of Directors And Matthew Buten, Chief Financial Officer United States
17 Nov 2021 Pfizer Announces Retirement of Chief Financial Officer Frank D’Amelio United States
12 Nov 2021 Pfizer names Bill Sessa, Ph.D., Chief Scientific Officer to lead internal medicine research United States
53
Business Expansion SAMPLE REPORT
Business expansion related news in the trailing 3 years.
Location Exposure Related Companies
Recent Developments
Announced Date Headline
28 Feb 2023 Tempus Enters into Co-Development Agreement with Pfizer
21 Feb 2023 Vysioneer announces data sharing agreement with Pfizer to augment oncology clinical trials with Artificial Intelligence
06 Jan 2023 Longevity Biotech Gero entered a research collaboration with Pfizer to discover potential targets for fibrotic diseases
26 Dec 2022 Pfizer expands its major manufacturing network in Kalamazoo, Michigan
54
Recent News SAMPLE REPORT
Date Headline Category Geography
14 Mar 2023 Pfizer signs agreement to acquire Seagen for $43bn M&A United States
Astellas announces phase 3 China ARCHES study of XTANDI meets primary

13 Mar 2023 Development, Launch & Termination United States
endpoint
10 Mar 2023 Pfizer’s ZAVZPRET (zavegepant) migraine nasal spray receives FDA approval Development, Launch & Termination United States
Pfizer and BioNTech submit for U.S. emergency use authorization of omicron
01 Mar 2023 Development, Launch & Termination Germany
BA.4/BA.5-adapted bivalent COVID-19 booster in children under 5 years
28 Feb 2023 Tempus Enters into Co-Development Agreement with Pfizer Business Expansion United States
Pfizer receives positive FDA Advisory Committee votes supporting potential

28 Feb 2023 Development, Launch & Termination United States
approval for vaccine candidate to help combat RSV in older adults
26 Feb 2023 Pfizer in talks to buy Seagen for likely for more than $30 bln M&A United States
Pfizer receives additional approval for Precedex as new sedative option for
24 Feb 2023 Development, Launch & Termination United States
children in Japan
Pfizer and BioNTech submit supplemental biologics license application for U.S.
24 Feb 2023 FDA approval of Omicron BA.4, BA.5-Adapted Bivalent COVID-19 Vaccine for Ages Development, Launch & Termination United States
12 Years and older as primary series or booster
22 Feb 2023 Pfizer’s Elranatamab receives FDA and EMA filing acceptance Development, Launch & Termination United States
55
SAMPLE REPORT
Pfizer Inc
Patent Strategy
56
Patent Publication Trends SAMPLE REPORT
Patenting activities (Grants, applications, and all publications) in the last 20 years.
9,000
8,000
7,000
6,000
Publication Count
5,000
4,000
3,000
2,000
1,000
0
2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022
Application 4098 5268 6231 4764 4130 3645 2487 1650 1474 1094 953 812 852 798 799 927 1026 945 1056 767
Grant 1869 2171 2004 1946 1407 1308 1105 959 740 656 584 577 693 558 573 416 475 491 542 398
All Publications 6143 7577 8435 6886 5709 5099 3686 2659 2269 1803 1571 1414 1560 1374 1380 1356 1515 1442 1612 1188
Note: Applications are the pre-grant publications and Grants are the post-grant publications of the patent applications 57
Patents by Authority SAMPLE REPORT
Authority-wise patent portfolio breakdown for the applications and grants in the last 20 years.
Applications Grants
AR CN
CN PT
5% 4%
6% US ZA 4%
MX 6%
23%
6% US
CA
BR 7% 33%
7%
AU
IL 7%
7%
AT
WO
7%
AU 18%
8%
ES EP
CA 9% 12%
EP DE
8%
12% 11%
Note: Please see appendix for Authority codes 58

Patents by Country SAMPLE REPORT
Patent publications by country in the last 20 years.
Country Count %
United States 12,524 19%
Canada 3,826 6%
Australia 3,703 6%
Israel 2,513 4%
China 2,487 4%
Brazil 2,440 4%
Mexico 2,032 3%
Germany 1,966 3%
Taiwan (Province of
1,755 3%
China)
Argentina 1,460 2%
Spain 1,437 2%
Japan 1,430 2%
South Korea 1,243 2%
Austria 1,072 2%
Denmark 948 1%
Note: Top Countries showcased are based on all publications.

59
IP Protection by Region SAMPLE REPORT
Regional distribution of patenting activity (Total Publications) in the last 20 years.
Europe Total Publications: 10,451

• Top patent offices Publication
contribution – Germany(1,966),
Spain(1,437), Austria(1,072)
• Top three themes – Rare Diseases(2,872),
Rare Diseases(1,084), Addiction(1,056)
North America Total Publications:

18,382
• Top patent offices Publication Asia Pacific Total Publications:
contribution – United States(12,524), 13,125
Canada(3,826), Mexico(2,032) • Top patent offices Publication
• Top three themes – Rare Diseases(7,625), contribution – Australia(3,703),
Addiction(2,617), Climate Change(881) China(2,487), Taiwan (Province of
China)(1,755)
• Top three themes – Rare Diseases(3,242),

Rare Diseases(1,478), Addiction(1,017)
South & Central America Total Publications:
7,322
• Top patent offices Publication contribution –
Brazil(2,440), Argentina(1,460), Peru(598)
Middle East & Africa Total Publications:
• Top three themes – Rare Diseases(2,562), 4,858
Addiction(925), Rare Diseases(469) • Top patent offices Publication contribution –
Israel(2,513), South Africa(850), Tunisia(210)
• Top three themes – Rare Diseases(1,195), Rare
Diseases(492), Addiction(395)
Note: National and regional patenting authorities are mapped to respective regions based on their jurisdictions. WIPO patents are not considered for the analysis. 60
Top Innovators SAMPLE REPORT
Key inventors by publications.
Shah Syed M 328
Fensome Andrew 315
Stack Gary Paul 297
Blake James F 288

Inventors
Cole Derek Cecil 280
Chakravarty Sarvajit 216
Khandke Lakshmi 215
Robichaud Albert Jean 202
Jiang Yutong 201
Haas Julia 187
0 50 100 150 200 250 300 350

Publication Count
61
Key Innovation Areas SAMPLE REPORT
GlobalData Technology foresight key innovation area based on number of patent filings during 2018-2022.
▪ Pfizer has collaborated with Roche in technologies

related to antineoplastic drugs which are used to
treat cancer
▪ Amgen has worked with Pfizer to develop
immunoglobulins [IGs], e.g., monoclonal or
polyclonal antibodies
▪ Non-steroidal anti-inflammatory drugs (NSAIDs)
and drugs for skeletal disorders are the major
focus while Pfizer collaborating with AstraZeneca
Note: Key innovation areas are identified from patent filings using a combination of machine and human intelligence.
*The analysis is run on patents filed between 2018 and 2022 62
Key Innovation Areas – Growth SAMPLE REPORT
The CAGR for the last year versus the previous three years signifies recent growth in the key innovation area for the company.
250
200 ▪ Pfizer has collaborated with Roche in technologies

related to antineoplastic drugs which are used to
treat cancer
150
▪ Amgen has worked with Pfizer to develop
1 year growth rate
immunoglobulins [IGs], e.g., monoclonal or

100 polyclonal antibodies
▪ Non-steroidal anti-inflammatory drugs (NSAIDs)
50 and drugs for skeletal disorders are the major
focus while Pfizer collaborating with AstraZeneca
0
-60 -40 -20 0 20 40 60 80
-50
-100 3 year CAGR
Bubble size = Patent Volumes

Note: Not all innovations are equal and nor do they follow a constant upward trend. The growth profile chart demonstrates the emergence of key innovation areas over time indicating a shift in innovation strategy/focus of a company.
*The analysis is run on patents filed between 2018 and 2022 63
SAMPLE
Leaders, Challengers and Laggards based on Innovation REPORT
Impact & Disruptive Potential
Pharmaceuticals and Healthcare Sector
GlobalData 3I innovation framework unpacks

companies’ innovation potential using novel
sources of data like patents, filings, and jobs
and ranks them on three pillars - Innovation
Intensity, Innovation Impact, and Innovation
Ingenuity based on 19 key innovation quality
and strength indicators.
• Innovation Intensity measures the

activity or quantity of innovation in the
organization.
• Innovation Impact measures the
external impact of the innovation
outside the organization.
• Innovation Ingenuity measures the
disruptive potential of the innovation
by the organization.
• The proprietary four-quadrant analysis

identifies the market leaders,
challengers, and laggards based on the
innovation impact and disruptive
potential of various companies. It
indicates that Pfizer is one of the
disruptive leaders and is ranked 10 in the
Pharmaceutical & Healthcare sector.
Note: The size of the bubble refers to the score in Innovation Intensity (activity of innovation)
64
Key CPC Classifications SAMPLE REPORT
The top 10 CPC classification (Main Group level) where the company has filed
most of the patents during past 20 years.
No. of Patent Publications - Overall

30,000
CPC Classification # Publications Description
24,412 24,359
25,000 A61P43/00 24412
A61P43/00 : Drugs for specific purposes, not provided for in groups A61P1/00-
A61P41/00
21,241
18,814 A61K31/00 24359 A61K31/00 : Medicinal preparations containing organic active ingredients
20,000
Deal Volume
A61P25/00 21241 A61P25/00 : Drugs for disorders of the nervous system

15,381
15,000 13,630 13,440 13,350
12,784 12,479 A61P35/00 18814 A61P35/00 : Antineoplastic agents
A61P9/00 15381 A61P9/00 : Drugs for disorders of the cardiovascular system

10,000
A61P3/00 13630 A61P3/00 : Drugs for disorders of the metabolism
5,000 A61P31/00 13440 A61P31/00 : Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
A61P29/00 : Non-central analgesic, antipyretic or anti-inflammatory agents, e.g

A61P29/00 13350
antirheumatic agents; Non-steroidal anti-inflammatory drugs
0
A61P1/00 12784 A61P1/00 : Drugs for disorders of the alimentary tract or the digestive system
A61P37/00 12479 A61P37/00 : Drugs for immunological or allergic disorders
65
Recent Applications SAMPLE REPORT
Publication Identifier Publication Date Document Type Application Number Title
US20230061858A1 02-Mar-23 Application US17786722 TREATMENT WITH SITE SPECIFIC HER2 ANTIBODY-DRUG CONJUGATES
US20230061743A1 02-Mar-23 Application US17827560 SUSTAINED RELEASE PHARMACEUTICAL COMPOSITIONS
US20230065881A1 02-Mar-23 Application US17934629 HETEROCYCLE SUBSTITUTED PYRIDINE DERIVATIVE ANTIFUNGAL AGENTS
EP4139616A1 01-Mar-23 Application EP21718593A CORONAVIRUS-IMPFSTOFF
CN115708827A 24-Feb-23 Application CN202211274002A 用于治疗异常细胞生长的组合物和方法
CN115715194A 24-Feb-23 Application CN202180040059A 治疗冠状病毒疾病2019的方法
AU2021297249A1 23-Feb-23 Application AU2021297249A Compositions and methods for treating obsessive-compulsive disorder
AU2021308406A1 23-Feb-23 Application AU2021308406A KAT6 inhibitor methods and combinations for cancer treatment
US2023060079A1 23-Feb-23 Application US17787454 SURFACE MODIFYING COATING FOR MEDICAL DEVICES
Stable pharmaceutical topical formulation containing immunosuppressant for treating dermatological
AU2021308340A1 23-Feb-23 Application AU2021308340A
conditions
US2023059489A1 23-Feb-23 Application US17849467 ANTIBODIES SPECIFIC FOR FLT3 AND THEIR USES
US20230060079A1 23-Feb-23 Application US17787454 SURFACE MODIFYING COATING FOR MEDICAL DEVICES
US2023055376A1 23-Feb-23 Application US17837622 5-HT2C RECEPTOR AGONISTS AND COMPOSITIONS AND METHODS OF USE
US20230055376A1 23-Feb-23 Application US17837622 5-HT2C RECEPTOR AGONISTS AND COMPOSITIONS AND METHODS OF USE
US20230059489A1 23-Feb-23 Application US17849467 ANTIBODIES SPECIFIC FOR FLT3 AND THEIR USES
66
Recent Applications SAMPLE REPORT
JP2023506638A 17-Feb-23 Application JP2022537025A 医療デバイスのための表面改質コーティング
US2023053328A9 16-Feb-23 Application US17613304 COMBINATION THERAPIES USING CDK INHIBITORS
US20230053328A9 16-Feb-23 Application US17613304 COMBINATION THERAPIES USING CDK INHIBITORS

MODULATORS OF THE BETA-3 ADRENERGIC RECEPTOR USEFUL FOR THE TREATMENT OR PREVENTION
WO2023017388A1 16-Feb-23 Application IB2022057313W
OF HEART FAILURE
AU2021297823A1 16-Feb-23 Application AU2021297823A Topical formulations of (1S)-1-phenyl-2-pyridin-2-ylethanamine
AU2021310520A1 16-Feb-23 Application AU2021310520A Recombinant vaccinia virus

CO-BEHANDLUNG MIT CDK4/6- UND CDK2-INHIBITOREN ZUR UNTERDRÜCKUNG DER
EP4132530A1 15-Feb-23 Application EP21719267A
TUMORANPASSUNG AN CDK2-INHIBITOREN
EP4132950A1 15-Feb-23 Application EP21720149A ZUSAMMENSETZUNGEN MIT DREI OSPA-FUSIONSPROTEINEN ZUR MEDIZINISCHEN VERWENDUNG
KRISTALLINE FORMEN VON 3-CYANO-1-[4-[(6-(1-METHYL-1H-PYRAZOL-4-YL)PYRAZOLO[1,5-A!PYRAZIN-4-
EP4132931A1 15-Feb-23 Application EP21718219A
YL!-1H-PYRAZOL-1-YL!CYCLOBUTANACETONITRIL UND VERWENDUNG DAVON
KR1020237000677
KR1020230022435A 15-Feb-23 Application 컴퓨터화된 주사기에서 정보 관리를 위한 시스템 및 방법
A
JP2023022258A 14-Feb-23 Application JP2022193529A ロルラチニブマレイン酸塩の結晶質形態
Ｓ１Ｐ１レセプター関連障害における使用のための（Ｒ）－２－（７－（４－シクロペンチル
JP2023022155A 14-Feb-23 Application JP2022187106A －３－（トリフルオロメチル）ベンジルオキシ）－１，２，３，４－テトラヒドロシクロペン
タ［ｂ］インドール－３－イル）酢酸（化合物１）の結晶性Ｌ－アルギニン塩
KR1020237001331
KR1020230022246A 14-Feb-23 Application 치료 항체 및 그의 용도
A
KR1020237003653
KR1020230021186A 13-Feb-23 Application PAH METHODS OF TREATING PAH WITH COMBINATIONS OF RALINEPAG AND OTHER AGENTS
A
KR1020237003231 IMMUNOGENIC COMPOSITIONS COMPRISING CONJUGATED CAPSULAR SACCHARIDE ANTIGENS AND
KR1020230021167A 13-Feb-23 Application
A USES THEREOF
67
Recent Grants SAMPLE REPORT
KRISTALLINE FORM VON (S)-N-(5-((R)-2-(2,5-DIFLUORPHENYL)-PYRROLIDIN-1-YL)-PYRAZOLO[1,5-
EP3699181B1 01-Mar-23 Grant EP20169707A
A]PYRIMIDIN-3-YL)-3-HYDROXYPYRROLIDIN-1-CARBOXAMID-SCHWEFELWASSERSTOFF
EP3000467B1 01-Mar-23 Grant EP15188350A BEHANDLUNGSSCHEMA MIT NERATINIB FÜR BRUSTKREBS
EP3555064B9 01-Mar-23 Grant EP17817174A GLP-1-REZEPTORAGONISTEN UND VERWENDUNGEN DAVON
EP3806855B1 01-Mar-23 Grant EP19759027A GLP-1-REZEPTORAGONISTEN UND VERWENDUNGEN DAVON
AU2019228377B2 23-Feb-23 Grant AU2019228377A Antibody purification
ZA202205794B 22-Feb-23 Grant ZA202205794A ONCE DAILY CANCER TREATMENT REGIMEN WITH A PRMT5 INHIBITOR
ES2934492T3 22-Feb-23 Grant ES19836351T Inhibidores de ferroportina y métodos de uso

US11584734B2 21-Feb-23 Grant US16639047 Tricyclic compounds as histone methyltransferase inhibitors
EP2498756B2 15-Feb-23 Grant EP10779339A NERATINIBMALEATTABLETTEN
EP3592741B1 15-Feb-23 Grant EP18711703A NEUARTIGE IMIDAZO[4,5-C]-CHINOLIN-DERIVATE ALS LRRK2-INHIBITOREN
EP3710439B1 15-Feb-23 Grant EP18879484A KRAS-G12C-INHIBITOREN
CA3077508C 14-Feb-23 Grant CA3077508A CRYSTALLINE FORM OF LORLATINIB FREE BASE HYDRATE
US11578428B2 14-Feb-23 Grant US16836986 Humanized antibodies
JP7222024B2 14-Feb-23 Grant JP2021094240A 上皮増殖因子受容体変異体ＩＩＩおよびＣＤ３の単一および二重特異性抗体およびそれらの使

用
JP7222021B2 14-Feb-23 Grant JP2021080099A 肺炎連鎖球菌ワクチンにおいて用いるための免疫原性組成物
68
Recent Grants SAMPLE REPORT
US11578087B2 14-Feb-23 Grant US17108066 Oxaborole esters and uses thereof
CN111201235B 10-Feb-23 Grant CN201880065709A 劳拉替尼游离碱水合物的结晶形式
JP7219732B2 08-Feb-23 Grant JP2020046453A Ｓ１Ｐ１受容体に関連する状態の処置方法
JP7219223B2 07-Feb-23 Grant JP2019549462A ＬＲＲＫ２阻害剤としての新規のイミダゾ［４，５－ｃ］キノリン誘導体
US11571424B2 07-Feb-23 Grant US16942094 Polymorphs of ARRY-380, a selective HER2 inhibitor and pharmaceutical compositions containing them
US11572370B2 07-Feb-23 Grant US16960534 CD16A binding agents and uses thereof
JP7218396B2 06-Feb-23 Grant JP2021066885A 二重特異性抗体

PL3463345T3 06-Feb-23 Grant PL807555T PHARMACEUTICAL COMBINATIONS
HRP20131438T1 03-Feb-23 Grant HRP20221438T GLYCOCONJUGATION PROCESS
HRP20171437T1 03-Feb-23 Grant HRP20221437T GLP-1 RECEPTOR AGONISTS AND USES THEREOF
CN108524931B 03-Feb-23 Grant CN201810670091A 糖缀合物
CN110087691B 03-Feb-23 Grant CN201780078019A 抗-EDB抗体和抗体-药物缀合物
AU2020204645B2 02-Feb-23 Grant AU2020204645A Multivalent pneumococcal polysaccharide-protein conjugate composition
AU2020204508B2 02-Feb-23 Grant AU2020204508A Streptococcus pneumoniae capsular polysaccharides and conjugates thereof
ES2933127T3 01-Feb-23 Grant ES18156289T Procedimiento de glucoconjugación
69
SAMPLE REPORT
Pfizer Inc
Management Outlook
70
Corporate Filings - Management vs. Analyst sentimentSAMPLE REPORT
Divergence Management Sentiment Analyst Sentiment
0.86 0.05
0.04
0.85 0.85 0.85 0.85
0.04
0.84 0.84
0.03
Divergence
Sentiment
0.83 0.03
0.82 0.04 0.82 0.04 0.02
0.02
0.81 0.81 0.81 0.81
0.01
0.80
0.01 0.01 0.01
0.79 0.00
2019 2020 2021 2022
The filings sentiment classification is done at a sentence level using a combination of an NLP and machine learning model.
The model is trained on sentences from filings documents and hence considers the context and is not a keyword approach. 71
Note: The analysis is based on earnings call transcripts
Sentiment and Mentions SAMPLE REPORT
0.86
0.85
0.84
Sentiment
0.83
0.82
0.81
0.80
0.79
2019 2020 2021 2022
Full Document Sentiment Score Management Sentiment Score Analyst Sentiment Score
Note: The analysis is based on earnings call transcripts
The filings sentiment classification is done at a sentence level using a combination of an NLP and machine learning model. 72
The model is trained on sentences from filings documents and hence considers the context and is not a keyword approach. Source: GlobalData Company Analytics
CXO Intent on R&D Investment SAMPLE REPORT
Filing Date CXO Quote
09 Nov 2022 Research and Development (R&D) ExpensesR&D expenses increased $15 million in the third quarter, primarily due to:•increased costs ...
13 Dec 2022 Robyn Kay Shelton Karnauskas - Truist Securities, Inc., Research Division - Research Analyst With the $90 billion, I think, number...
12 Dec 2022 Pfizer market research 2021-2022 ; 3.Preliminary – scientific and commercial feasibility being evaluated Note: Preliminary, subje...
01 Nov 2022 The 2% operational increase in adjusted R&D expense in Q3 was primarily driven by increased cost to develop recently acquired asse...
18 Nov 2022 We are – we think there is – I think there is a good balance between how do we think about research and development in allocating ...
73
CXO Intent on Human Capital SAMPLE REPORT
Human capital KPIs include employee engagement, female and US minority representation, pay equity, and opportunity parity.
Initiatives from latest ESG and Annual Report Focus Area
7-9 GRI 400: Social Disclosures GRI Index — Continued Appendix Goal 6 Goal 12 Goal 14 Goal 15 Goal 6 Goal 12 Goal 14 Goal 15 Goal 5 Goal 8 Goal
10 Goal 3 Goal 8 Clean Water and Sanitation Responsible Consumption and Production Life Below Water Life on Land Clean Water and Sanitation Diversity and Inclusion
Responsi...
A full copy of the report can be found at: https://gender-pay-gap.service.gov.uk/ Our 2025 Opportunity Parity Goals By 2025, we aim to achieve
Workforce Parity
global workforce parity of 47% for women at the VP level and above.
Annual revenue for ReViral's RSV programs, if successful, has the potential to reach or exceed(1) 15 First Quarter 2022 Earnings Business
Development Strategy: Partner of Choice for Biotechs 16 First Quarter 2022 Earnings Russia & Ukraine Business Ethics ESG Update (1 of 2) Pay Equity Pay Equity
Diversity, E...
74
Theme Exposure SAMPLE REPORT
Theme Mentions and Sentiment in the trailing 12 months.
Intellectual
Innovation Covid-19 ESG Deal Making Healthcare Environment Geopolitics Demographics M&A
Property
Mentions 872 768 635 373 355 281 279 267 242 195
Intellectual
Innovation Covid-19 ESG Deal Making Healthcare Environment Geopolitics Demographics M&A
Property
Sentiment 0.69 0.66 0.77 0.59 0.52 0.73 0.64 0.63 0.34 0.66
75
Mentions & Growth by Region SAMPLE REPORT
Geography Mentions in the trailing 12 months.
Europe data
Mentions 142
Mentions Growth -15%
North America
Asia Pacific data
695 Mentions
Mentions 97
-22% Mentions Growth
South & Central America

681 Mentions Middle East & Africa data
-21% Mentions Growth Mentions 45
76
Location Exposure SAMPLE REPORT
Location Mentions and Sentiment in the trailing 12 months.
Middle East United

North America United States Europe Asia-Pacific China Japan Russia Ukraine
and Africa Kingdom
Mentions 695 681 142 97 49 45 43 36 34 26
Middle East United

North America United States Europe Asia-Pacific China Japan Russia Ukraine
and Africa Kingdom
Sentiment 0.60 0.61 0.61 0.67 0.42 0.82 0.82 1.00 0.29 0.61
77
Recent Filings SAMPLE REPORT
Filing Type Filing Date Sentiment score Sentences
Other Filings 07 Mar 2023 0.90 270

Other Filings 31 Jan 2023 0.50 14
Transcripts 31 Jan 2023 0.85 611
Other Filings 13 Dec 2022 0.88 1798
Other Filings 12 Dec 2022 0.60 578
Other Filings 18 Nov 2022 0.72 266
Quarterly Reports 09 Nov 2022 0.43 691
Transcripts 01 Nov 2022 0.85 567
Other Filings 21 Oct 2022 0.73 435
Other Filings 20 Oct 2022 0.43 46
78
Note: Sentences represent the number of statements analysed from the filings to calculate sentiment. Source: GlobalData Company Analytics
SAMPLE REPORT
Pfizer Inc
Hiring Strategy
79
Hiring Trends SAMPLE REPORT
4,000 7,000
3,500 6,000
3,000
No. of Posted/Closed Jobs
5,000
No. of Active Jobs

2,500
4,000
2,000
3,000
1,500
2,000
1,000
500 1,000
0 0
Mar-22 Apr-22 May-22 Jun-22 Jul-22 Aug-22 Sep-22 Oct-22 Nov-22 Dec-22
Closed 992 1384 1829 1638 1753 1619 1545 1819 2288 3358
Posted 742 1670 1679 1503 1583 1287 1417 1517 1607 3218
Active 5985 6271 6121 5986 5816 5484 5356 5054 4373 4233
80
Theme Exposure SAMPLE REPORT
Top themes from new job postings in the trailing 12 months.
Theme Posted Jobs Growth (%) Job Duration (Days)
Global Macro Outlook 7,335 -51.22 42
Foreign Direct Investments (FDI) 5,250 -46.19 38
US Macro Outlook 3,410 -53.42 44
Digitalization 2,195 -37.21 39
Future of Work 1,544 -45.61 42
China Macro Outlook 1,464 -53.49 36
Big Data 1,372 -46.99 48
Europe Macro Outlook 1,336 -50.66 45
Smart Hospitals 1,244 40.3 45
Social 944 -45.62 43
81
Note: A single job posting can be tagged to multiple themes. Source: GlobalData Company Analytics
Hiring by Location SAMPLE REPORT
Job postings by location in the trailing 12 months.
United States China Mexico Brazil Switzerland Belgium United Kingdom India Germany Philippines
14,623 1,159 1,137 952 840 811 742 638 532 476
Note: Top Countries showcased are based on job postings.

82
Global Talent Hotspots SAMPLE REPORT
Key locations from new job postings, and growth in the trailing 12 months.
83
Technical Skills Map SAMPLE REPORT
A map of the most sought-after technical skills based on job postings growth and job duration in the trailing 12 months.
39
38
38
Job Duration (Days)
37
37
36
36
35
35
-25 -20 -15 -10 -5 0
Posted Jobs, Growth (%)
Communication Skills Office Productivity Applications Administrative Skills Analytical Skills Leadership Skills
Organizational Skills Personal Skills Technical Skills Presentation Skills Project Management Skills
84
Soft Skills Map SAMPLE REPORT
A map of the most sought-after soft skills based on job postings growth and job duration in the trailing 12 months.
39
38
38
37
Job Duration (Days)
37
36
36
35
35
34
34
-18 -16 -14 -12 -10 -8 -6 -4 -2 0
Communication Skills Analytical Skills Administrative Skills Leadership Skills
85
Key Occupations SAMPLE REPORT
Key Occupations based on US O*NET Standard Occupation Classification.
Occupation Growth(%) Posted Jobs Job Duration (Days)
Medical Records Specialists -13.65 1,645 27
General and Operations Managers -23.12 908 36
Biological Scientists -5.75 869 47
Medical Scientists -11.3 416 45
Sales Representatives, Wholesale and Manufacturing 199.08 326 27
Computer and Information Systems Managers -25.43 302 40
Maintenance and Repair Workers, General -20.26 244 35
Software and Web Developers, Programmers, and Testers 26.46 239 42
86
Days to Hire / Skill shortage SAMPLE REPORT
Average number of days to job closure. An increase indicates inability to close jobs or skill shortages, a decrease indicates faster job closures.
Job Duration: Days to Job Closure by month
Mar-22 Apr-22 May-22 Jun-22 Jul-22 Aug-22 Sep-22 Oct-22 Nov-22 Dec-22
53 47 42 37 37 34 29 21 14 43
87
Hiring Intensity by Seniority SAMPLE REPORT
Job Postings by Seniority
Junior Level Mid Level Entry Level Senior
Pfizer Inc 6,406 5,219 3,636 956
88
Senior Management Hiring SAMPLE REPORT
Recent Senior roles
Maintenance Tech IV, SVP R3 Director, Business Assessment, Team Lead/Director, Rare Rare Disease Content and
Director Market Access (m/w/d)
Nights Internal Medicine and Digital Disease RWE Scientist Education Director nMD
Director, Small Molecule Director RSV Vaccines Value & Medical Director, Migraine, NA
SVP Maintenance Supervisor Director Surgical Portfolio
Business Operations Evidence Medical Affairs, non-MD
Vice President, Head of Global Clinical Lead Benign

Sr. Director Product & Platform Director, Data Science, Business
Strategic Partnerships, Partner Director - Engineering Hematology - MD (Executive
Engineering Lead Analytics & Insights (E)
of Choice Director)
Sr. Production Equipment

Senior Director, External Director, Rare Disease RWE Global Solids Manufacturing
Senior Director, External Supply Operator – SVP Aseptic
Supply – Primary Care Scientist Cluster Lead – Vice President
Equipment Cleaning
Pfizer CentreOne Global Brand Director, Comirnaty Launch Project Management and
Myfembree Director, Consumer
and Marketing Campaigns Operations Leader (Director) Planning, IDN, & Employer Continuous Improvement
Marketing
Director Strategy Director (Vaccines R&D)
89
SAMPLE REPORT
Pfizer Inc
Social Media & Ad Strategy
90
Twitter Influencer Mention Trend SAMPLE REPORT
Trailing 12-month mentions trend by influencers on Twitter
Total Tweets Total Influencers Posts Growth % (Y-o-Y) Net Sentiment*

26658 3299 (-70%) 0.38
3,500
3,026
3,000 3,015
2,500
2,354 2,297
2,209
2,000
1,862
1,738
1,669
1,500 1,527
1,423
993
1,000 886 925
739 784 779
713 693
642
515
500
0
Mar 2022 Apr 2022 May 2022 Jun 2022 Jul 2022 Aug 2022 Sep 2022 Oct 2022 Nov 2022 Dec 2022
Influencers Tweets
91
*The Net sentiment score is calculated as ratio of Count of Positives and (Count of Positives + Count of Negatives) Source: GlobalData Company Analytics
Net Sentiment Trend SAMPLE REPORT
Trailing 12-month sentiment trend
Net Sentiment* Positive Posts Negative Posts Neutral Posts

0.38 4953 15176 23977
0.40
0.35
0.30
0.25
Net Sentiment
0.20
0.15
0.10
0.05
0.00
92
Top Influencer Discussions on Twitter SAMPLE REPORT
Trailing 12-month mentions intensity on Twitter
93
Pfizer: Twitter Analysis SAMPLE REPORT
Follower Growth Content Types
500,000
498,000 6%
496,000
494,000
Tweets
492,000
Retweets
490,000
488,000 +7,087 over last 30 days

486,000 94%
Usually Posts about Top Campaigns
#MultipleMyeloma 352
12
#ScienceWillWin 1391
11
#AMR 261
8
#TwitterSpaces 238
8
Total Engagements Total Posts

94
Pfizer: Twitter Analysis SAMPLE REPORT
Audience Analysis
Followers location Followers classification

Total Followers 497,585
2% 236
3%
12% United States
GD Influencers 478
Others
13% 105
United Kingdom
69 64 62
Industry Leaders 14 Canada
70% India
Media Accounts 5 Pharma & Medical Expert CXO/Founder Technology Expert
*Location collected for 425 accounts *Influencer categories collected for 456 accounts
Most Influential Followers Most Engaged posts
Suhasini Ha.. 1,358,886 Scott Gottl.. 573,900

@suhasinih Editor/Journal.. @ScottGottliebM Academician
D
Alexander S.. 469,656 Marcus Samu.. 439,541
@alexstubb Academician @MarcusCooks Food & Beverag..
Jennifer Gu.. 367,595 Glen Gilmor.. 287,435

@DrJenGunter Doctors @GlenGilmore Social Media I..
Melissa Fra.. 258,799 James Rosen 230,680

@MelissaAFranci Editor/Journal.. @JamesRosenTV Editor/Journal.. 95
s 12066 likes, 889 RTs 3667 likes,
Source: GlobalData 4144 RTs
Company Analytics
*Latest Follower counts as on January 31, 2023
Redditor Mention Trend SAMPLE REPORT
Trailing 12-month mentions trend by Redditors
Total Posts Total Redditors Posts Growth % (Y-o-Y) Net Sentiment*

17448 9126 (-82%) 0.17
2,500
1,979
2,000 1,863
1,805
1,689
1,635
1,518
1,500 1,356
1,296
1,252 1,238
1,165 1,145
1,092 1,069 1,010 1,020
970
1,000 866
757
703
500
0
Redditors Posts
96
Top Redditor Discussions SAMPLE REPORT
Trailing 12-month mentions intensity on Reddit
97
Media Activity Trend SAMPLE REPORT
Trailing 12-month mentions trend by media & publishing handles
Posts Growth %
Total Tweets Total Media Accounts Net Sentiment*
(Y-o-Y)
7526 450 0.56
(-55%)
1,000
900 888 874
800
778
700
643
600 615
500 485 494 503 490

470
400
300
207 221
196
200 165 168 166 160
139 138 134
100
0
Media Outlets Posts
98
Top Media Discussions SAMPLE REPORT
Trailing 12-month discussions intensity
99
Most Popular Tweets from Media SAMPLE REPORT
Pfizer Inc
The Guardian NPR The New York Times
@guardian @NPR @nytimes
Pfizer accused of Covid profiteering as first-quarter sales JUST IN: The FDA authorized reformulated COVID boosters Breaking News: The FDA authorized second booster shots
hit $26bn https://t.co/35uXHTBYeY from Moderna and Pfizer that target the original of the Pfizer and Moderna vaccines for everyone 50 and
coronavirus strain and the omicron BA.4/BA.5.....more older and some immunocompromised people......more
http://twitter.com/guardian/statuses/1521486979719913478 http://twitter.com/NPR/statuses/1564985221258387457 https://twitter.com/nytimes/status/1508819296834801675
2498 Retweets | 4954 Likes 1137 Retweets | 3163 Likes 1389 Retweets | 2603 Likes
Reuters Top News The New York Times The New York Times
@Reuters @nytimes @nytimes
U.S. FDA, CDC see early signal of Pfizer bivalent COVID Breaking News: The Biden administration plans to offer Breaking News: Moderna sued Pfizer and BioNTech,
shot's link to stroke https://t.co/gcZtkKmmXa updated Covid boosters in September, with reformulated accusing them of copying the central technology behind its
https://t.co/bhvZjIWZXq doses expected from Pfizer and Moderna......more coronavirus vaccine. https://t.co/c5VI9uMX.....more
http://twitter.com/Reuters/statuses/1614078706170970112 http://twitter.com/nytimes/statuses/1552815933080899584 http://twitter.com/nytimes/statuses/1563147142059147265
2736 Retweets | 4539 Likes 963 Retweets | 3069 Likes 718 Retweets | 1763 Likes
100
SAMPLE REPORT
Pfizer Inc
Competitive Benchmarking
101
Company Benchmarking: Key Facts SAMPLE REPORT
Pfizer Inc

United States of Pharmaceuticals and 1849 $2,23,976m $1,00,330m 83,000
America Healthcare
Company Summary
Pfizer Inc (Pfizer) discovers, develops, manufactures, and commercializes biopharmaceuticals. The company offers products to treat various conditions such as cardiovascular,
metabolic and pain, women’s health, cancer, inflammation, immune disorders, and rare diseases. It also provides sterile injectable pharmaceuticals, biosimilars, active
pharmaceutical ingredients (APIs) and contract manufacturing services. Pfizer sells its products through wholesalers, retailers, hospitals, individual provider offices, clinics,
government agencies and pharmacies. It has major manufacturing facilities in India, China, Japan, Ireland, Italy, Belgium, Germany, Singapore, and the US. The company
provides its products in North America, South America, Asia-Pacific, Australia, Europe, Africa, and the Middle East. Pfizer is headquartered in New York, the US.
AbbVie Inc
Pharmaceuticals and 2013

United States of $2,68,860m $58,054m 50,000
America Healthcare
Company Summary
AbbVie Inc (AbbVie) is a specialty biopharmaceutical company, which discovers, develops, manufactures, and commercializes drugs for the treatment of chronic and complex
diseases. Its drugs are indicated for the treatment of metabolic and rheumatological diseases, neurological disorders, skin diseases, rheumatoid arthritis, pain related to
endometriosis, pediatric Crohn's disease, cancer, and other serious health conditions. AbbVie is also advancing its pipeline programs for the treatment of Crohn's disease,
Parkinson's disease, viral diseases, wet AMD, various cancers, neurological disorders, aesthetics, and other autoimmune diseases. The company markets its products directly
to wholesalers, distributors, health care facilities, government agencies, specialty pharmacies and independent retailers through its own distribution centers and public
warehouses worldwide. AbbVie is headquartered in North Chicago, Illinois, the US.
102
Johnson & Johnson

United States of Pharmaceuticals and 1887 $3,98,612m $94,943m 1,52,700
America Healthcare
Company Summary
Johnson & Johnson (J&J) researches, develops, manufactures, and sells pharmaceutical products, medical devices, and consumer products. The company provides
pharmaceuticals for immune diseases, cancer, neurological disorders, infectious, cardiovascular, and metabolic diseases consumer products in oral care, baby care, beauty,
over the counter (OTC) medicines, women’s health and wound care categories and medical devices for use in the cardiovascular, orthopaedic, neurovascular care, general
surgery and vision care fields. J&J distributes pharmaceutical and medical products to retailers, wholesalers, health care professionals and hospitals and offers consumer
products through retail outlets and distributors. The company offers its products in the US Europe Asia-Pacific and Africa and Western Hemisphere (excluding the US). J&J is
headquartered in New Brunswick, New Jersey, the US.
Merck & Co Inc

Pharmaceuticals and 1851 $2,68,405m $59,283m 68,000
United States of
Healthcare
America
Company Summary
Merck & Co Inc (Merck) is a biopharmaceutical company focused on the discovery, development, manufacturing and marketing of prescription medicines, biologic therapies,
vaccines and animal health products. It offers prescription products for therapy areas related to cardiovascular, cancer, immune disorders, infectious, respiratory and women's
diseases, and diabetes. The company provides animal health products such as vaccines, poultry products, livestock products and aquaculture products. Merck sells medicines
to drug wholesalers, retailers, hospitals, government agencies and managed health care providers and animal health products to veterinarians, distributors and animal
producers. The company and its subsidiaries operate in the Americas, Europe, the Middle East, Africa, Asia Pacific, and Latin America. Merck is known as MSD outside the US
and Canada and is headquartered in Kenilworth, New Jersey, the US.
103
F. Hoffmann-La Roche Ltd

Switzerland Pharmaceuticals and 1896 $2,33,962m $66,291m 1,03,613
Healthcare
Company Summary
F. Hoffmann-La Roche Ltd (Roche) is a biotechnology company that develops drugs and diagnostics to treat major diseases. It provides medicines for the treatment of
cancer, other auto-immune diseases, central nervous system disorders, ophthalmological disorders, infectious diseases, and respiratory diseases. The company also
offers in vitro diagnostics, tissue-based cancer diagnostics, and diabetes management solutions. Roche conducts research to identify novel methods to prevent,
diagnose, and treat diseases. The company offers its products and services to hospitals, commercial laboratories, healthcare professionals, researchers, and
pharmacists. Together with its subsidiaries and partners, the company has operations in various countries. Roche is headquartered in Basel, Switzerland.
104
Competitive Benchmarking: Financials SAMPLE REPORT
Comparative analysis of Key financials and growth ratios
Key financials
Johnson & Johnson F. Hoffmann-La Roche Ltd

Pfizer Inc (2022) AbbVie Inc (2022) Merck & Co Inc (2022)
(2022) (2022)
Total Revenue US$ (m) 1,00,330 58,054 94,943 59,283 66,281
Net Income US$ (m) 31,372 11,836 17,941 14,519 13,010
Operating Income US$ (m) 36,551 18,117 21,725 17,945 18,304
Gross Profit US$ (m) 65,739 41,527 63,954 42,077 46,892
Growth ratios
(2022) (2022)
Sales Growth 23.43% 3.30% 1.25% 21.72% 0.76%
Operating Income Growth 54.54% 1.08% -4.61% 43.12% -3.74%
EBITDA Growth 44.28% 0.53% -4.88% 38.74% -5.66%
Net Income Growth 42.73% 2.55% -14.07% 11.27% -10.83%
*Note: Based on latest reported financials, as available. 105

Competitive Benchmarking: Ratios SAMPLE REPORT
Comparative analysis of profitability ratios
Profitability ratios

(2022) (2022)
Gross Margin 65.52% 71.53% 67.36% 70.98% 70.75%
Operating Margin 36.43% 31.21% 22.88% 30.27% 27.62%
Net Profit Margin 31.27% 20.39% 18.90% 24.49% 19.63%
Return on Equity 32.80% 68.60% 23.36% 31.57% 44.37%
Debt to Equity Ratio 0.37% 3.67% 0.52% 0.67% 0.95%
Net Debt to Equity 0.14% 3.13% 0.21% 0.38% 0.60%
Debt to Capital Ratio 0.27% 0.79% 0.34% 0.40% 0.49%
*Note: Based on latest reported financials, as available. 106

Competitive Benchmarking: Deal Volume SAMPLE REPORT
Summary of the deal volume in the last 5 years
F. Hoffmann-La
Deal Type Pfizer Inc AbbVie Inc Johnson & Johnson Merck & Co Inc
Roche Ltd
Acquisition 17 12 21 30 14
Asset Transaction 14 9 26 6 8
Merger - - - 1 -
Equity Offering 42 4 7 13 6
Debt Offering 19 19 6 14 2
Venture Financing 68 32 96 82 52
Private Equity 7 2 17 5 -
Partnership 163 70 166 216 221
Top Location North America Europe North America North America North America
Top Technology Theme Artificial Intelligence Digitalization Artificial Intelligence Internet of Things Artificial Intelligence
J.P. Morgan The Goldman Sachs

Top Financial Advisor The Goldman Sachs Group Inc Morgan Stanley Citigroup Inc
Securities LLC Group Inc
Cravath, Swaine &
Top Legal Advisor Goodwin Procter LLP Goodwin Procter LLP Goodwin Procter LLP Goodwin Procter LLP
Moore LLP
Most Recent Deal (Date) 13 Mar 2023 10 Jan 2023 08 Mar 2023 08 Mar 2023 09 Feb 2023 107
Competitive Benchmarking: Deal Value SAMPLE REPORT
Summary of the deal value in the last 5 years
F. Hoffmann-La
Deal Type Pfizer Inc AbbVie Inc Johnson & Johnson Merck & Co Inc
Roche Ltd
Acquisition 83,710.21 87,575.35 35,471.5 29,811.85 13,755.76
Asset Transaction 1,767 825.7 823.2 115 213.1
Merger - - - - -
Equity Offering 4,626.48 20.1 893.9 2,207.66 413.6
Debt Offering 17,845 39,470.68 7,500 17,502.5 1,400
Venture Financing 4,680.96 1,570.44 4,046.81 4,827.34 2,575.47
Private Equity 871 197.1 3,259.45 188.2 -
Partnership 21,787.96 13,697 15,978 48,391.36 67,310.42
Top Location North America Europe North America North America North America
Top Technology Theme Artificial Intelligence Digitalization Artificial Intelligence Internet of Things Artificial Intelligence
J.P. Morgan Goldman Sachs & Co Goldman Sachs & Co

Top Financial Advisor Centerview Partners LLC Citigroup Inc
Securities LLC LLC LLC
Davis Polk & Cravath, Swaine & Covington & Burling Davis Polk &
Top Legal Advisor Wachtell, Lipton, Rosen & Katz
Wardwell LLP Moore LLP LLP Wardwell LLP
Most Recent Deal (Date) 13 Mar 2023 10 Jan 2023 08 Mar 2023 08 Mar 2023 09 Feb 2023
108
Competitive Benchmarking: Deals Technology Theme SAMPLE REPORT
Exposure (by Volume)
Top Technology themes exposure of deals in the last 5 years by volume.
Theme Name Pfizer Inc AbbVie Inc Johnson & Johnson Merck & Co Inc F. Hoffmann-La Roche Industry
18 - 35 15 18 789
6 1 12 - 11 130
Digitalization
8 - 17 12 9 179
Big Data
3 - - - - 51
Cloud
1 - - - - 4
Edge Computing
- - 18 - 5 -
Robotics
- - 13 12 - -
Internet of Things
- - - 2 1 -
Future of Work
- - - 5 - -
Digital Media
109
Note: A single deal can be tagged to multiple themes. Source: GlobalData Company Analytics
Competitive Benchmarking: Deals Technology Theme SAMPLE REPORT
Exposure (by value)
Top Technology themes exposure of deals in the 5 years by value.
Theme Name Pfizer Inc Johnson & Johnson Merck & Co Inc F. Hoffmann-La Roche Industry
946 1,154 1,381 578 62,694

128 419 - 71 22,472

Digitalization
430 369 825 1,930 6,387

Big Data
430 - - - 1,149
Cloud
- 6,687 - 106 -
Robotics
- 5,856 4,004 - -
Internet of Things
- - 163 - -
Future of Work
- - 281 - -
Digital Media
- - - - 402
Edge Computing
110
Note: A single deal can be tagged to multiple themes. Source: GlobalData Company Analytics
Competitive Benchmarking: Deals Location Exposure SAMPLE REPORT
Location exposure of deals in the last 5 years
Deal Volume
F. Hoffmann-La Roche
Region Pfizer Inc AbbVie Inc Johnson & Johnson Merck & Co Inc
Ltd
Industry
North America 235 95 213 299 158 16,154
South and Central America 5 5 2 7 5 389
Middle East and Africa 11 4 18 8 7 816
Europe 69 26 73 62 116 5,976
Asia-Pacific 41 9 38 62 34 5,935
Deal Value
Region Pfizer Inc AbbVie Inc Johnson & Johnson Merck & Co Inc
Ltd
Industry
North America 1,21,771 48,388 54,182 64,514 49,257 15,20,531
South and Central America 1,770 2,270 264 3,379 2,860 78,138
Middle East and Africa 1,913 2,270 556 2,068 2,867 89,453
Europe 6,254 92,030 3,149 6,874 30,145 7,77,324
Asia-Pacific 3,518 3,969 2,872 4,918 5,566 4,44,579
111
Note: A single deal can be tagged to multiple regions. Source: GlobalData Company Analytics
Competitive Benchmarking: Patents SAMPLE REPORT
Summary of patent activity in the trailing 12 months
AbbVie Inc Johnson & Johnson Merck & Co Inc Pfizer Inc
Ltd
Patent Filings 445 (-60%) 3,244 (-22%) 6,249 (-13%) 948 (-27%) 726 (-24%)
Patent Publications 682 (-61%) 5,041 (-25%) 10,415 (-8%) 1,459 (-33%) 1,159 (-20%)
Patent Grants 228 (-61%) 1,735 (-30%) 3,998 (+0%) 426 (-46%) 412 (-16%)
Patent Grants/Patent Filings 0.51 (-2%) 0.53 (-10%) 0.64 (+14%) 0.45 (-26%) 0.57 (+12%)
Top CPC Classification A61K31/00 (-61%) C07K16/00 (-33%) A61B17/00 (-24%) A61K31/00 (-38%) A61K31/00 (-27%)
Top Location United States (-51%) United States (-15%) United States (-12%) United States (-22%) United States (-37%)
Top Theme Cell & Gene Therapy (-71%) Healthtech (-4%) Healthtech (-16%) Climate Change (-56%) Climate Change (-16%)
Top Sector Healthcare (-66%) Healthcare (-40%) Healthcare (-22%) Healthcare (-42%) Healthcare (-36%)
112
Competitive Benchmarking: Hiring SAMPLE REPORT
Summary of hiring activity in the trailing 12 months.
Johnson & Johnson AbbVie Inc Merck & Co Inc Pfizer Inc
Ltd
Jobs Active 1,741 1,900 2,334 1,779 2,141
Jobs Posted 27,783 10,237 17,575 16,566 16,225
Jobs Closed 31,011 12,835 19,223 21,829 20,321
Days to Job Closure 52 125 104 132 136
General and Operations General and Operations General and Operations Software and Web Developers,
Top Occupation Medical Records Specialists
Managers Managers Managers Programmers, and Testers
United States of America 11,502 United States of America 7,492 (- United States of America 5,972 United States of America 3,256 United States of America 5,941 (-
Top Location (Posted)
(-17%) 9%) (124%) (1%) 12%)
Global Macro Outlook 17,228 (- Global Macro Outlook 7,129 (- Global Macro Outlook 8,384 (- Foreign Direct Investments (FDI) Global Macro Outlook 7,181 (-
Top Theme (Posted)
29%) 39%) 3%) 8,338 (-28%) 50%)
Senior Roles (Posted) 1,735 (-33%) 1,065 (-31%) 1,832 (97%) 323 (8%) 915 (-12%)
M&A Roles (Posted) 407 (83%) 54 (29%) 70 (169%) 54 (29%) 70 (-12%)
Innovation Roles (Posted) 1,246 (-51%) 374 (-69%) 949 (-5%) 526 (-30%) 796 (-52%)
113
Competitive Benchmarking: Hiring Trends SAMPLE REPORT
120
100
80
Active jobs index
60
40
20
0
F. Hoffmann-La Roche Ltd Pfizer Inc Johnson & Johnson AbbVie Inc Merck & Co Inc
114
Competitive Benchmarking: Hiring - Job Postings SAMPLE REPORT
Comparative analysis of job postings in the trailing 12 months.
45
40
35
30
Job Duration (Days)
25
20
15
10
0
-30 -20 -10 0 10 20 30 40 50 60 70
Johnson & Johnson Merck & Co Inc F. Hoffmann-La Roche Ltd Pfizer Inc AbbVie Inc
115
Competitive Benchmarking: Social Media Mentions SAMPLE REPORT
Summary of Social media mentions in the trailing 12 months.
Pfizer Inc AbbVie Inc Johnson & Johnson Merck & Co Inc
Ltd
Total Posts 44,106 (-77%) 2,873 (+10%) 3,016 (-70%) 5,451 (-61%) 4,068 (+4%)
Total Tweets 26,658 (-70%) 2,107 (+8%) 1,884 (-63%) 4,546 (-60%) 2,626 (-1%)
Total Influencers 3,299 (-63%) 429 (-12%) 488 (-66%) 966 (-60%) 708 (-23%)
Total Reddit Posts 17,448 (-82%) 766 (+19%) 1,132 (-76%) 905 (-64%) 1,442 (+18%)
Total Redditors 9,126 (-80%) 570 (+25%) 903 (-74%) 544 (-64%) 926 (-1%)
Total Twitter Engagements 1,76,37,512 32,395 57,395 1,61,982 38,067
Average Twitter Engagement 661 15 30 35 14
Net Sentiment 0.37 (+18%) 0.65 (+45%) 0.79 (+15%) 0.7 (+25%) 0.63 (+46%)
#pharma
Top Trending Hashtags #pfizer #COVID19 #pharma #pharma #IBD #AbbVie #johnsonandjohnson #pharma #Merck #biotech #pharma #Roche #biotech
#COVID19
116
SAMPLE
Competitive Benchmarking - Share of Voice (SoV) Analysis REPORT
Share of Voice for Pfizer Inc & it’s competitors by volume
7%
9%
Pfizer Inc
5%
AbbVie Inc
5%
Johnson & Johnson
Merck & Co Inc
F. Hoffmann-La Roche Ltd
74%
Share of voice pie is based on volume of posts for the period: 12 months
Share of voice pie is based on volume of posts for the period: 1st Jan 2022 to 31st Dec 2022
117
SAMPLE
Competitive Benchmarking - Share of Voice (SoV) Analysis REPORT
Growth %
Growth in Volume Growth in Contributors
F. Hoffmann-La Roche Ltd 4 63%
Merck & Co Inc -61 70%
Johnson & Johnson -70 79%
AbbVie Inc 10 65%
Pfizer Inc -77 37%
118
Competitive Benchmarking - Social Ad Strategy SAMPLE REPORT
Pfizer Roche Merck J&J
Twitter Followers 497,565 247,442 226,098 250,242
Total Tweets Shared 463 538 358 385
Total Engagement 63,417 10,690 5,784 2,637
Average Engagements 137 19 16 6
Number of posts per day 1.27 1.47 0.98 1.05
*Notes: Analysis is based on posts published by company’s global Twitter and LinkedIn accounts over last 30 days
1. Total Engagements is the sum of Likes and Retweets received on posts shared
2. Average engagement/post is ratio of Total Engagements and Total Posts
119
3. #GD Influencers are set of Twitter influencers across industries tracked by GlobalData Source: GlobalData Company Analytics
SAMPLE REPORT
Appendix
120
Patent Authority Codes SAMPLE REPORT
Code Authority Code Authority Code Authority
US United States of America CO Colombia MX Mexico
WO WIPO DK Denmark MN Mongolia

(World Intellectual Property Organization)
EP European Patent Office EG Egypt NL Netherlands
CA Canada FI Finland NZ New Zealand
IL Israel FR France NO Norway
AU Australia GE Georgia PA Panama
BR Brazil GR Greece PH Philippines
CN China HK Hongkong PL Poland
MX Mexico IS Iceland RO Romania
JP Japan IN India RU Russia
KR South Korea IT Italy SG Singapore
TW Taiwan JO Jordan ES Spain
DE Germany KZ Kazakhstan SE Sweden
AT Austria KE Kenya CH Switzerland
BE Belgium LV Latvia TR Turkey
BR Brazil LU Luxembourg GB United Kingdom
CL Chile MY Malaysia ZW Zimbabwe

121
Glossary SAMPLE REPORT
Term Description
News Sentiment Highlights positive, negative, and neutral impressions for news.
Hiring Trend Analysis of job postings made by a company on its career page.
Database of filings made by public companies including IPO prospectus, Annual reports, Quarterly reports, Earnings
Company Filing
transcripts, Investor presentations, ESG reports etc.
Score for filings released by the company, leveraging advanced ML and NLP model at the sentence level. The sentiment is
Filing Sentiment
scored between 0 and 1. Higher the score, the better is the sentiment.
Themes Key topics arising from new technologies, macroeconomic shifts, and social trends.
122
Field Name Description
Combination of two or more companies into one company. The company which issues shares as consideration to target company shareholders
Merger is called Surviving Company (Transferee Company). The company whose shareholders receive shares is called Target Company (Transferor
Company).
When one company or group of companies acquire an equity stake in another company or when a company or group of companies disposing
Acquisition
off their stake(s) in the other company through a secondary market transaction.
When one company acquires asset/property/business division related to another company. Assets may include property, facilities, business
Asset Transaction
division, operations, brands, etc.
Equity Offering A deal, in which Issuer Company sells an ownership stake in it to investors to raise capital.
The issuance of debt securities comprises either convertible security like convertible debt, convertible senior note or non-convertible as in
Debt Offering
senior note, etc. Usually, these securities have a maturity date, coupon and conversion price (in case of convertible debt securities).
Partnership A Partnership is a business transaction in which two or more companies together undertake certain business operations.
A deal is classified as a private equity deal if the acquirer is a private equity firm, with the exception to transactions where a PE firm acquiring
Private Equity
another PE firm.
Venture Financing Venture financing (VF) involves providing capital to startups and small businesses with exceptional growth potential.
A license is a contractual right that gives someone permission to engage in a defined activity or to use certain property that is owned by
Licensing Agreement
someone else.
Contract Service Agreements indicates the service offered by a Contract Manufacturing Organization (CMO): Active Pharmaceutical Ingredient
Contract Service Agreement
(API) manufacture, Dosage Form manufacture, Packaging, or Analytical Services.
123
Term Definition
Patent Patent is the document defining a right conferred by the grant but is often used to mean published specification
Assignee An individual or group of people who have the permission or right to manufacture or license an invention by the inventor, bound by contract
Application date The date on which the application, which contains disclosure of the invention is submitted to the patent office
The publication date is the date on which a patent application is first published. It is the date on which the document is made available to the
Publication date public, thereby making it part of the state of the art. A publication date range can be selected based on the user's requirement to search for prior
art between the date ranges
These are pre-grant publications published by a patent authority once the patent is filed by an applicant. In most authorities, the patents are
Filings
usually published within 18 months from the date of filing depending on the patent laws of that authority
Grant These are patent documents issued/granted by the patent authority as per patent laws in the patent authority
Patent Offices The public body which received and grants patents in each country
International Patent Classification (IPC) is a hierarchical classification system used to classify and search patent documents according to the
IPC
technical fields they pertain.
Cooperative Patent Classification (CPC) is an extension of the IPC and is jointly managed by the EPO and the US Patent and Trademark Office. It is
CPC
divided into nine sections, A-H and Y, which in turn are sub-divided into classes, sub-classes, groups and sub-groups.
Themes Key topics arising from new technologies, macroeconomic shifts, and social trends.
Measures the number of different applications identified for each relevant patent and broadly splits companies into either ‘niche’ or ‘diversified’
Application diversity
innovators
Refers to the number of different countries each relevant patent is registered in and reflects the breadth of geographic application intended,
Geographic reach
ranging from ‘global’ to ‘local’
124
Term Description
Job Title Job Title, as available from the employer.
Job Description Job description as posted by the employer.
Posted Jobs New job postings for a given time period.
Closed Jobs Jobs closed/removed from the career page of the employer.
Active Jobs Jobs available for application on the employer career page.
Days to Close / Job Duration

Number of days from a new job posting to the removal/closure on the career page of the employer.
(Days)
Job Growth Year-on-year jobs growth in %.
The base value is defined as 100 and rest of the values are benchmarked against the base. This helps with relative
Index
comparison.
The S&Ps 500, is a stock market index tracking the performance of 500 large companies listed on stock exchanges in
S&P 500 Index
the United States.
125
Term Description
GlobalData’s Social Media Analytics platform allows businesses to understand brand sentiments, product led conversations, buzzing trends among
Social Media Analytics Platform Twitter Influencers and Redditors tracked by GlobalData, by using a combination of AI and human based analysis that curate content and displays only
what matters to you.
Number of contributors which include Twitter Influencers, Media accounts and Reddit Authors, who have posted content related to the search.
Total Contributors
Twitter Influencer Number of unique Twitter handles of industry experts/individuals tracked by GlobalData who posted content related to a search.
Redditors Number of unique reddit accounts who have posted content related to a search.
Total Posts Count of all posts which include tweets, reddit posts and reddit comments
For Twitter, engagements are calculated as sum of Likes and Retweets. For Reddit, Engagements are calculated as sum of upvotes and number of
Engagement
comments.
Engagement Rate Ratio of total engagements by total posts.
Global Score is calculated based on weights assigned to parameters like average content engagements, follower network, number of times other
Global Score
Influencers tracked by GlobalData have referred them in content, and content relevancy.
Average reaction It is calculated as total engagements (Total Likes + Total Retweets) / Total Posts shared during the period.
126
Additional Resources SAMPLE REPORT
➢ AbbVie Inc Strategy Report
➢ Johnson & Johnson Strategy Report
➢ Merck & Co Inc Strategy Report
➢ F. Hoffmann-La Roche Ltd Strategy Report
127
About GlobalData
GlobalData is a leading provider of data, analytics,

and insights on the world's largest industries.
In an increasingly fast-moving, complex, and uncertain world, it has
never been harder for organizations and decision makers to predict
and navigate the future. This is why GlobalData’s mission is to help
our clients to decode the future and profit from faster, more
informed decisions. As a leading information services company,
thousands of clients rely on GlobalData for trusted, timely, and
actionable intelligence. Our solutions are designed to provide a daily
edge to professionals within corporations, financial institutions,
professional services, and government agencies.
Unique Data Expert Analysis Innovative Solutions One Platform

We continuously update and enrich We leverage the collective expertise We help you work smarter and We have a single taxonomy across
50+ terabytes of unique data to of over 2,000 in-house industry faster by giving you access to all of our data assets and
provide an unbiased, authoritative analysts, data scientists, and powerful analytics and integrate our capabilities into a
view of the sectors, markets, and journalists, as well as a global customizable workflow tools single platform – giving you easy
companies offering growth community of industry professionals, tailored to your role, alongside access to a complete, dynamic,
opportunities across the world's to provide decision-makers with direct access to our expert and comparable view of the
largest industries. timely, actionable insight. community of analysts. world’s largest industries.
128
A connected platform for a dynamic world
GlobalData Insight
Unique Data. Expert Analysis. Innovative Solutions. One Platform.
Find more actionable sector-specific insights to help elevate

your business strategy using GlobalData’s Intelligence Centers.
Our comprehensive business solution will help you to exploit

market opportunities more effectively.
Use the Intelligence Center to:

• Predict future trends
• Streamline decision-making
• Design winning customer propositions
• Identify profitable sales segments
Find Out More
129
Contact us – a global network of offices
CENTRAL & NORTH AMERICA EUROPE ASIA Shanghai
SOUTH AMERICA London Beijing Room 408,
Boston Tower No: 1701,
Bogota 41 Farnsworth St, John Carpenter House Room 2301 Bulding 4
7 Carmelite Street Wanda Plaza, West Bejing Road
Calle 71, MA 02210, USA Jing'an District, 200040,
No 5-23 Suite 501 D +1 781 762 9450 EC4Y 0BS, UK No 93 Jianguo Road
+44 207 936 6400 Chaoyang District Shanghai, PR China
+571 3470749 +86 21 5157 2275(6)
Beijing 100026, PR China
New York + 86 10 6581 1794
Buenos Aires 441 Lexington Avenue, Basingstoke +86 10 5820 4077
Basavibaso 1328, 2nd Floor NY 10017, USA Singapore
4th Floor, Northern Cross 50, Raffles Place
Off 206, Buenos Aires +1 646 395 5460 Basing View, Hampshire
1006 CA, Argentina Hyderabad Unit 38-04A
+54 11 4311 5874 RG21 4EB, UK KRISHE SAPPHIRE, Singapore Land Tower
San Francisco +44 1256 394200 MSR Block, 3rd Floor, 048623
425 California Street, Madhapur, +65 6383 4688
Mexico City Suite 1300 Hyderabad-500081, +65 6383 5433
Mote Pelvoux 111-2 Piso CA 94104, USA Hull
Shirethorn House Telangana, India
Lomas de Chapultepec +1 415 800 0336 +91 40 6616 6700
Mexico D.F, 11000 37-43 Prospect Street Tokyo
+52 55 5284 2945 HU2 8PX, UK Level 3,
Toronto Hong Kong Sanno Park Tower,
530 Richmond St West 1008 Shatin Galleria 2-11-1 Nagata-cho,
Suite 300 Manchester
Churchgate House 18-24 Shan Mei Street Chiyoda-ku,
AUSTRALIA M5V 1Y4, Ontario, Canada Fo Tan, New Territories Tokyo, 100-616, Japan
+1 703 788 3592 M1 6EU, UK
Melbourne +44 161 359 5813 Hong Kong S.A.R T: +81 3 6205 3511
Suite 1608 +852 2690 5200 F: +81 3 6205 3521
Exchange Tower , Virginia +852 2690 5230
Business Centre 9870 Main Street, Fairfax, Madrid
530 Little Collins Street Virginia 22031, USA C/Jesusa Lara,
29 - Atico J, Seoul
3000, Victoria Toll-free in USA: 24th floor, City Air Tower, MIDDLE EAST
+61 3 9909 7757 +1 888 777 9940 28250 Torrelodones,
Spain Teheranro 87gil Dubai
+61 3 9909 7759 Direct: +1 703 383 4903 36, Samsung Dong,
Fax: +1 703 383 4905 +34 91 859 4886 Dubai Media City
Gangnam Gu, Building 7, Floor 3,
Sydney Republic Of Korea Office 308
Suite 602, level 6 Paris (Postcode 06164)
Les Bureaux de Sevres PO Box 502635
45 Clarence St T: +82 2 2016 6070 United Arab Emirates
Sydney 2000 2, rue Troyon M: +82 10 8976 2437
92316 Sevres, France +971 4391 3049
+61 2 8076 8815 F: +82 2 2016 5411
130
Contact Us
For any questions or further

enquiries please contact us at:
marketing@globaldata.com
Disclaimer: © GlobalData Plc. All Rights Reserved. This information has been extracted from
GlobalData Intelligence Center by a registered user. No part of this publication may be reproduced,
stored in a retrieval system or transmitted in any form by any means, electronic, mechanical,
photocopying, recording or otherwise, without the prior permission of the publisher, GlobalData.
The facts of this report are believed to be correct at the time of publication but cannot be guaranteed.
Please note that the findings, conclusions and recommendations that GlobalData delivers will be based
on information gathered in good faith from both primary and secondary sources, whose accuracy we
are not always in a position to guarantee. As such GlobalData can accept no liability whatever for
actions taken based on any information that may subsequently prove to be incorrect. GlobalData is not
authorized or permitted to provide regulated investment advice. Any data or analysis provided by
GlobalData, either verbally or in writing, should not be considered as regulated investment advice.
131

StrategyReport Sample

Uploaded by

Copyright:

Available Formats

You might also like

StrategyReport Sample

Uploaded by

Document Information

Original Description:

Original Title

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

StrategyReport Sample

Uploaded by

Copyright:

Available Formats

SAMPLE REPORT

Unique Data. Expert Analysis. Innovative Solutions. One Platform.

Published: 17 Mar 2023

Key Facts M&A Strategy Location Exposure

Company Financials Capital Raising Strategy Recent Filings

SWOT Analysis Strategic Alliances & Partnerships HIRING STRATEGY

Key Executives RECENT DEVELOPMENTS Hiring by Location

News Trend and Sentiment Key Occupations and Skills

Key Themes Key Lists Peers Key Investments Key Acquisitions

Revenue Net Income EPS ($)

2018 40,825 11,152 1.1

2019 41,172 16,273 1.2

2020 41,651 9,159 1.5

2018 2019 2020 2021 2022

8,618 8,828 8,372

4,090 4,022 4,036

2018 2019 2020 2021 2022

Note: see appendix for region details 6

R&D spending as a % of Revenue R&D Expenses (US$M)

18.9% 18.8% 22.4%

• Reported revenue of US$13,833.0 million for FY2022, which

Aamir Malik Executive Vice President Senior Management 2021 47

Dan R. Littman, M.D., Ph.D. Director Non Executive Board 2018 70

Helen H. Hobbs, M.D. Director Non Executive Board 2011 70

James C. Smith Director Non Executive Board 2014 63

James Quincey Director Non Executive Board 2020 58

Joseph J. Echevarria Director Non Executive Board 2015 65

Industry News Deals Filings All KPIs

Technology, Media and Telecom

Government and Non-Profit Organisations

Aerospace and Defence

Retail & Wholesale

Transportation, Infrastructure and Logistics

Power & Utilities

Industrial Goods & Machinery

Business and Consumer Services

Oil & Gas

Headquarters Key locations & Subsidiaries

134 138 125

Trials with CROs by Phase Outsourced drugs by Molecule Type

Packager Dose Manufacturer API Manufacturer

PMG Research Inc 51

Sarah Cannon Research Institute LLC 46

IQVIA Holdings Inc 33

Syneos Health Inc 28

PRA Health Sciences Inc 27

Anaheim Clinical Trials-LLC 26

Parexel International Corp 26

Miami Research Associates LLC 25

No. of Clinical Trials

Remote Patient Monitoring

Real World Evidence

Pharma Valuation Screen

Internal development and maintenance spend 1,215

External spend 2,356

Total ICT spend by function, 2022 Total IT spend by channel, 2022

10% Data Centre Technology